Cell double barcoding systems and use thereof

The double barcoding system allows for the simultaneous measurement of multiple transcription factors and miRNAs by using libraries of nucleic acid vectors with unique barcodes, addressing the limitations of existing systems in evaluating drug effects and cell heterogeneity, thereby enhancing cancer research capabilities.

WO2024236583A1PCT designated stage expired Publication Date: 2024-11-21ARIEL SCI INNOVATIONS LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/IL2024/050490
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-18
Filing Date
2024-05-19
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

Current cell DNA barcoding systems lack the ability to simultaneously measure multiple transcription factors or miRNAs and assess the heterogeneity of their activities within a cell population, limiting their effectiveness in evaluating drug effects on cell signaling and overall cell physiology, particularly in cancer research.

Method used

Development of a double barcoding system using libraries of nucleic acid vectors with unique first and second barcodes, allowing for the simultaneous measurement of transcription factor and miRNA activities by contacting cell populations with these vectors and identifying barcode sequences to quantify their activities.

Benefits of technology

Enables the quantitative evaluation of drug effects on cell signaling and heterogeneity in cancer cell populations, improving the monitoring of cancer cell behavior and drug responses, with enhanced sensitivity and resolution compared to existing methods.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IL2024050490_21112024_PF_FP_ABST
    Figure IL2024050490_21112024_PF_FP_ABST
Patent Text Reader

Abstract

Libraries of nucleic acid vectors wherein each vector comprises a promoter comprising a sequence of a DNA-associated protein binding site, and a first nucleic acid barcode, wherein the promoter is operatively linked to the first barcode are also provided. Libraries of nucleic acid vectors wherein each vector comprises a promoter, a microRNA binding site and a first nucleic acid barcode, wherein the promoter is operatively linked to the microRNA binding site and first barcode are also provided. Kits, and viral libraries comprising the libraries of nucleic acid vectors are also provided as are methods of using the same.
Need to check novelty before this filing date? Find Prior Art

Description

CELL DOUBLE BARCODING SYSTEMS AND USE THEREOFCROSS REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of priority of Israeli Patent Application No. 303055, filed May 18, 2023, the contents of which are all incorporated herein by reference in their entirety.REFERENCE TO AN ELECTRONIC SEQUENCE LISTING

[0002] The contents of the electronic sequence listing (ARL-P-042-PCT.xml; Size: 36,600 bytes; and Date of Creation: May 14, 2024) is herein incorporated by reference in its entirety.FIELD OF INVENTION

[0001] The present invention is in the field of cellular DNA barcoding.BACKGROUND OF THE INVENTION

[0002] Reporter plasmids are widely used in biomedical research. They allow for the measuring of various parameters of normal and disease cells, e.g. activities of various transcription factors or miRNAs. These reporter plasmids have several critical drawbacks: (a) they do not allow multiplexing, i.e. simultaneous measurements of multiple transcription factors or miRNAs, and (b) they do not allow assessment of heterogeneity of activities of these factors within a cell population.

[0003] Cell DNA barcoding was introduced a number of years ago to study various aspects of tumor development. There are various systems for cell barcoding, including direct introduction of barcodes via lentiviral infection, CRISPR-based barcoding, or combination of barcoding with fluorescent markers for isolation of individual clones of interest. These barcoding systems allowed dissecting many novel aspects of tumor dynamics, metastasis and drug effects. The barcoding approach, however, has not been effectively used for the quantitative evaluation of drugs effects on cell signaling or overall cell physiology. Understanding drug effects on signalling is critical for uncovering mechanisms of resistance, designing effective drug combinations and personalization of treatments. Evaluating the heterogeneity of signallingresponses in cancer cell populations is especially important for elucidating resistance mechanisms. A system that allows for quantitative measurements of transcription factors activities and miRNAs in cell culture, primary tumors and metastases without these drawbacks is greatly needed.SUMMARY OF THE INVENTION

[0004] The present invention provides libraries of nucleic acid vectors wherein each vector comprises a sequence of a short hairpin RNA or a CRISPR guide RNA and a first nucleic acid barcode are provided. Libraries of nucleic acid vectors wherein each vector comprises a promoter comprising a sequence of a DNA-associated protein binding site, a first nucleic acid barcode and a second nucleic acid barcode, wherein the promoter is operatively linked to the first and second barcodes are also provided. Libraries of nucleic acid vectors wherein each vector comprises a microRNA (miR) binding site, a first nucleic acid barcode and a second nucleic acid barcode are also provided. Kits, and viral libraries comprising the libraries of nucleic acid vectors are also provided as are methods of using the same.

[0005] According to a first aspect, there is provided a library of nucleic acid molecule vectors, wherein each vector of the library comprises: a. a promoter comprising a sequence of a DNA-binding protein binding site and a sequence of a minimal promoter; and b. a first nucleic acid barcode; wherein the first nucleic acid barcode is unique to each vector of the library; wherein the first nucleic acid barcode is operably linked to the promoter, and the library contains a plurality of vectors with the same sequence of a DNA-binding protein binding site and each vector of the plurality of vectors comprises a unique first barcode.

[0006] According to some embodiments, each vector of the library further comprises a second nucleic acid barcode unique to the DNA binding protein binding site, and wherein the plurality of vectors with the same sequence of a DNA-binding protein binding site comprise the same second nucleic acid barcode.

[0007] According to some embodiments, the library comprises vectors with a DNA-binding protein binding site for at least 2 different DNA-binding proteins.

[0008] According to some embodiments, the library comprises vectors with a DNA-binding protein binding site for at least 10 different DNA-binding proteins.

[0009] According to some embodiments, the library contains a plurality of vectors with the same sequence of a DNA-binding protein binding site for each of the at least 2 different DNA- binding proteins.

[0010] According to some embodiments, the library contains a plurality of vectors with the same sequence of a DNA-binding protein binding site for each of the at least 10 different DNA-binding proteins.

[0011] According to some embodiments, the DNA-binding protein is a transcription factor.

[0012] According to some embodiments, the DNA-binding protein is a component of a histone binding complex.

[0013] According to some embodiments, the DNA-binding protein is component of a DNA- modification complex.

[0014] According to some embodiments, the promoter comprises a repeat of the sequence of a DNA-binding protein binding site.

[0015] According to another aspect, there is provided a library of nucleic acid molecule vectors, wherein each vector of the library comprises a constitutively active promoter operably linked to: a. a transcribable region; b. a microRNA (miR) binding site; and c. a first nucleic acid barcode; wherein the first nucleic acid barcode is unique to each vector of the library; wherein the library contains a plurality of vectors with the same miR binding site and each vector of the plurality of vectors comprises a unique first barcode.

[0016] According to some embodiments, each vector of the library further comprises a second nucleic acid barcode unique to the miR binding stie, and wherein the plurality of vectors with the same miR binding site comprises the same second nucleic acid barcode.

[0017] According to some embodiments, the library comprises vectors with a miR binding site for at least 2 different miRs.

[0018] According to some embodiments, the library comprises vectors with a miR binding site for at least 10 different miRs.

[0019] According to some embodiments, the library contains a plurality of vectors with the same miR binding site for each of the at least 2 different miRs.

[0020] According to some embodiments, the library contains a plurality of vectors with the same miR binding site for each of the at least 10 different miRs.

[0021] According to some embodiments, the transcribable region is an open reading frame encoding a protein.

[0022] According to some embodiments, the protein is a fluorescent reporter protein.

[0023] According to some embodiments, the miR binding site is within a 3’ untranslated region (UTR) of the open reading frame.

[0024] According to some embodiments, the nucleic acid molecule vectors are viral DNA or RNA vectors.

[0025] According to some embodiments, the viral DNA or RNA vectors are capable of integrating the promoter, the second nucleic acid barcode and the first nucleic acid barcode into a genome of a cell infected by a virus comprising the viral vectors.

[0026] According to some embodiments, the viral vectors are selected from retroviral vectors, lentiviral vectors and adeno-associated viral vectors.

[0027] According to some embodiments, the plurality comprises at least 5 vectors wherein each of the at least 5 vectors comprises a different first barcode.

[0028] According to some embodiments, the first nucleic acid barcode, the second nucleic acid barcode or both comprises a nucleic acid sequence not found within a genome of a target cell.

[0029] According to some embodiments, the first nucleic acid barcodes are predetermined sequences selected such that each vector of the library comprises a first nucleic acid barcode with a unique sequence.

[0030] According to some embodiments, the first nucleic acid barcode is a randomly generated sequence.

[0031] According to some embodiments, the library has been sequenced such that the DNA- binding protein binding site or the miR binding site and the randomly generated sequence of each vector is known.

[0032] According to some embodiments, the library further comprises a linker sequence between the first nucleic acid barcode and the second nucleic acid barcode.

[0033] According to another aspect, there is provided a kit comprising at least two libraries of vectors of the invention, wherein each of the at least two libraries further comprises a third nucleic acid barcode and where a first library comprises a different third nucleic acid barcode from a third nucleic acid barcode of a second library.

[0034] According to some embodiments, the first nucleic acid barcodes, the second nucleic acid barcodes or both of the first library are the same as the first nucleic acid barcodes, second nucleic acid barcodes or both of the second library.

[0035] According to some embodiments, the kit further comprises at least one helper plasmid comprising an open reading frame encoding at least one viral gene required for production of infection-competent virus.

[0036] According to another aspect, there is provided a viral library wherein each virion of the library comprises a viral vector from a library of the invention.

[0037] According to another aspect, there is provided a kit comprising at least two viral libraries of the invention, wherein each of the at least two libraries further comprises within the viral vectors a third nucleic acid barcode and where a first library comprises a different third nucleic acid barcode from a third nucleic acid barcode of a second library.

[0038] According to another aspect, there is provided a method of simultaneously measuring activity of at least two transcription factors in a population of cells, the method comprising: a. contacting a population of cells with a library of the invention to produce a barcoded population of cells; b. identifying sequences of first and second barcodes on the same nucleic acid molecule within the double-barcoded cells, wherein the amount of a first second barcode is proportional to the activity of a first transcription factor and the amount of a second second barcode is proportional to the activity of a second transcription factor; thereby simultaneously measuring activity of at least two transcription factors.

[0039] According to another aspect, there is provided a method of simultaneously measuring activity of at least two transcription factors in a population of cells, the method comprising:a. contacting a population of cells with a library of the invention to produce a barcoded population of cells; b. identifying sequences of first barcodes on nucleic acid molecules within the barcoded cells, wherein the amount of all first barcodes known to be on vectors comprising a first DNA-binding protein binding site is proportional to the activity of a first transcription factor and the amount of all second first barcodes known to be on vectors comprising a second DNA-binding protein binding site is proportional to the activity of a second transcription factor; thereby simultaneously measuring activity of at least two transcription factors.

[0040] According to another aspect, there is provided a method of simultaneously measuring activity of at least two miRs in a population of cells, the method comprising: a. contacting a population of cells with a library of the invention to produce a barcoded population of cells; b. identifying sequences of first and second barcodes on the same nucleic acid molecule within the double-barcoded cells, wherein the amount of a first second barcode is inversely proportional to the activity of a first miR and the amount of a second second barcode is inversely proportional to the activity of a second miR; thereby simultaneously measuring activity of at least two miRs.

[0041] According to another aspect, there is provided a method of simultaneously measuring activity of at least two miRs in a population of cells, the method comprising: a. contacting a population of cells with a library of the invention to produce a barcoded population of cells; b. identifying sequences of first barcodes on nucleic acid molecules within the barcoded cells, wherein the amount of all first barcodes known to be on vectors comprising a first miR binding site is inversely proportional to the activity of a first miR and the amount of all second first barcodes known to be on vectors comprising a second miR binding site is inversely proportional to the activity of a second miR;thereby simultaneously measuring activity of at least two miRs.

[0042] According to some embodiments, the vectors are viral DNA or RNA vectors and the contacting comprises infecting the population of cells with the library.

[0043] According to some embodiments, the infecting results in integration of the second nucleic acid barcode and the first nucleic acid barcode into the population of cells.

[0044] According to some embodiments, the identifying comprising extracting nucleic acid molecules from the cells and detecting the presence of a nucleic acid molecule comprising the second nucleic acid barcode and the first nucleic acid barcode in the extracted nucleic acid molecules.

[0045] According to some embodiments, the identifying comprises next generation sequencing or barcode- specific PCR.

[0046] According to some embodiments, the method further comprises contacting the barcoded population of cells with a test condition prior or contacting the population of cells with a test condition prior to step (a).

[0047] According to some embodiments, the test condition comprises contacting the doublebarcoded population of cells with a therapeutic agent.

[0048] According to some embodiments, the therapeutic agent is a toxic agent and the target phenotype is cell survival or growth.

[0049] According to some embodiments, the method comprises within the identified sequences quantifying the number of nucleic acid molecules comprising each second barcode and each distinct first nucleic acid barcode thereby quantifying the number of specific clones and / or the number of cells in each clone of cells with each second barcode.

[0050] According to some embodiments, the population of cells are administered to a nonhuman subject and the method is a method of simultaneously measuring in vivo activity of at least two transcription factors or at least two miRs.

[0051] According to some embodiments, the method is for quantifying and / or tracking transcription factor activity in a cancer metastasis.

[0052] According to some embodiments, the population is selected from a cancer cell line, primary tumor cells and a patient-derived cancer cell population.

[0053] Further embodiments and the full scope of applicability of the present invention will become apparent from the detailed description given hereinafter. However, it should beunderstood that the detailed description and specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.BRIEF DESCRIPTION OF THE DRAWINGS

[0054] Figures 1A-1D: Double cell barcoding system allows monitoring primary tumors and metastasis derived from several cell lines simultaneously. (1A) The structure of the double barcoding system. (IB) Metastatic ability of MDA-MB231 and A549 cell lines. The data reflects relative representation of barcodes corresponding to MDA-MB231 and A549 cell lines in primary tumors and lung and liver metastasis. (1C) A significant fraction of clones that form metastasis in lungs can also form metastasis in liver. (ID) The ability to form metastasis does not correlate with the growth of cells in primary tumors (red columns). However, the ability to populate both lungs and liver closely correlates with the rate of growth in these organs (blue columns)

[0055] Figures 2A-2D: Measuring effects of treatment with doxorubicin on metastasis formed by A549 cells. (2A) Effects of doxorubicin on the number of clones (individual barcodes) corresponding to A549 metastasis. (2B) Effects of doxorubicin on the number of reads corresponding to A549 metastasis. (2C) Effects of doxorubicin on the clonal size distribution of liver metastasis of A549 cells. (2D) Effects of doxorubicin on the clonal size distribution of lung metastasis of A549 cells.

[0056] Figures 3A-3D: Measuring of effects of double drug treatments in primary tumors and metastasis. (3A) Measuring of effects of Osimertinib and FX9847 and their combination on xenograft tumor growth. Xenografts were established with H1975 lung cancer cells, and mice (10 animals per group) were treated with either Osimertinib or FX9847 or their combination as described in the Materials and Methods. Tumors were measured by the caliper. (3B) Sensitivity of Hl 975 and A549 cells to Osimertinib (24 hours of incubation). Cell viability was measured by the XTT assay. (3C) Effects of Osimertinib and FX9847 and their combination on the primary tumors. The number of reads corresponding to Hl 975 cells was normalized by the number of reads that represent A549 cells. (3D) Size distribution of clones in primary tumors of control population and animals treated with Osimertinib, FX9847 and their combination.

[0057] Figures 4A-4B: Measurement of representation of cell lines in the primary tumors and metastasis using qPCR approach. (4A) Representation of Hl 975 and A549 cells in primary tumors was quantified by the number of the corresponding reads. To normalize for the presence of inhibitors of PCR in DNA isolates, we spiked control DNA into the samples and normalized by its presence. (4B) Additional normalization of data for Hl 975 cells by drugresistant A549 cells increases the significance of the effects.

[0058] Figure 5A-5C: Effects of Osimertinib and FX9847, alone or in combination on clonal size distribution. (5A) Size distribution of clones in lung metastasis of control population and animals treated with Osimertinib, FX9847 and their combination. (5B-C) (5B) Line graph and (5C) scatter plot of barcode distribution in primary tumors.

[0059] Figures 6A-6B: Effects of irinotecan alone or in combination with 5-Azacytidin on clonal size distribution. 5-Azacytidin sensitizes cells to irinotecan. HCT116 cells were treated with irinotecan alone or irinotecan in combination with 5 -Aza, and cell death was measured. Of note, 5-Azacytidin alone did not show any toxicity. (6A) Size distribution of clones of heterogenous cell population either untreated or treated with irinotecan or irinotecan + 5-Azacytidin. (6B) Size distribution of clones of homogenous cloned cell population either untreated or treated with irinotecan or irinotecan + 5-azacytidin.

[0060] Figures 7A-7D: (7A) Carton of the set up of a CRISPR or shRNA screen. (7B) Cartoon of cell growth that can lead to a selected colony of cells. In a true hit (left) all cells that receive the knockdown / out continue to proliferate even in the presence of the drug. In a false-positive hit (right) most of the cells that receive the knockdown / out are killed by the drug, but due to heterogeneity at least one of cells proliferates not do due the knockdown / out but due to an intrinsic resistance in that cell. (7C) The structure of a double barcoded shRNA molecule of the invention. It will be understood that a CRISPR gRNA could be present in place of the shRNA. (7D) Diagram of the analysis of shRNA molecules pooled from the surviving cells after a screen. The target of shRNA-2 is considered a true hit due to the mix of various first barcodes, indicating that all cells that received the knockdown were resistant. In contrast, the target of shRNA-5 is considered a false-positive hit as only one first barcode is detecting indicting that only one particular close that received the shRNA survived.

[0061] Figure 8: The structure of a double barcoded transcription factor reporter library of the invention. Barcode 1 identifies the DBP that is active. Barcode 2 provides information of individual cells and heterogeneity of DBP activity. Barcode 3 labels the library and allows for mixing of cell populations bearing different libraries.

[0062] Figures 9A-9B: (9A) Graph of relative values of activities of a set of TFs (BC1 RNA), their presence in the cell population (BC1 DNA), and the result of normalization (BC1 RNA / BC1 DNA). (9B) Graph of distributions of activities of two TFs (YAP and Hifl) within the cell population.

[0063] Figure 10: The structure of a double barcoded miR reporter library of the invention. The sequence encoding the reporter molecule (a fluorescent molecule such as GFP) contains within its 3’ UTR a miR binding site. Barcode 1 identifies the miR that binds in the 3’ UTR. Barcode 2 provides information of individual cells and heterogeneity of miR activity. Barcode 3 labels the library and allows for mixing of cell populations bearing different libraries.DETAILED DESCRIPTION OF THE INVENTION

[0064] The present invention, in some embodiments, provides libraries of nucleic acid vectors wherein each vector comprises a sequence of a short hairpin RNA or a CRISPR guide RNA and a first nucleic acid barcode. Libraries of nucleic acid vectors wherein each vector comprises a promoter comprising a sequence of a DNA-binding protein binding site, a first nucleic acid barcode and a second nucleic acid barcode, wherein the promoter is operatively linked to the first and second barcodes are also provided. Libraries of nucleic acid vectors wherein each vector comprises a promoter, a coding region, a miRNA binding site, a first nucleic acid barcode and a second nucleic acid barcode, wherein the promoter is operatively linked to the coding region, miRNA binding site, and the first and second barcodes are also provided. Kits comprising the libraries of nucleic acid vectors are also provided. Viral libraries comprising virions comprising the libraries of nucleic acid vectors are also provided. Methods of genetic screening and methods of simultaneously measuring activity of at least two transcription factors or at least two miRNAs using the libraries of the invention are also provided.

[0065] The invention is based on the surprising finding of a novel barcoding system that allows monitoring the fate of individual clones in multiple cell populations. In particular the system allows for the simultaneous measurement of activities of multiple transcription factors (TFs) or miRNAs (miRs) with single clone resolution. This allows for the monitoring of drug effects on TFs and miRs and by extension their effects on heterogenous cancer cell populations in cell culture, tumors and metastases. Besides monitoring activities of TFs and miRs, the system allows for quantitatively monitoring cancer cell behavior and drug responses in animals inbasic research and preclinical studies. Currently used approaches that involve imaging or direct measurements with caliper suffer from relatively low sensitivity and low resolution, leading to the inability to quantitatively evaluate the number of metastasis and sizes of individual metastasis. There have been reports of measurements of metastasis by cell barcoding, but they have not been used for quantitative evaluation of drug effects and metastatic spread. Furthermore, in the majority of prior publications, only visible metastatic lesions were used to isolate barcodes and thus evaluate metastatic capacities of cancer cells. Such isolation of metastatic lesions only, which prevents overall monitoring of metastasis, was needed because in the overall distant organ, only a small fraction of cells is cancerous and therefore barcoded, and isolation of barcodes becomes technically difficult. This development allows isolation of RNA and DNA from the whole organ without focusing of the metastatic lesions, and therefore, one can see barcodes from all, even invisible, metastasis present in the organ and evaluate the number and size of each of them and activities of TFs and miRs in these metastases.

[0066] An important advantage of the double barcoding system over a single barcoding with random barcodes is that it allows for evaluating the number of metastasis and their sizes, while allowing internal normalization, which strongly enhances statistical significance of the results. The deviation in measurements of cancer parameters and drug responses between animals within a group are of two different origins: (1) difference between animals themselves (e.g., difference in their epigenetic origin), and (2) technical differences in the process of isolation of DNA from primary tumors and distant organs. Normalization with the double barcoding system allow correction of both sources of deviations. Indeed, when both drug-sensitive and drug-resistant cell lines were injected in a mouse, both experience similar host effects on tumor development and metastasis, and DNA from both lines is isolated with similar technical details. Indeed, when the deviation from average was compared with and without normalization by the second cell line, it was observed that the normalization strongly reduces the deviations (Fig. 3D), thus allowing the use of a relatively small number of animals per group to achieve the statistical significance.

[0067] Further, effects of drugs measured by the barcode sequencing were stronger than the effect measured by caliper. In fact, by day seven of exposure, when measuring by caliper about a 4-fold difference from control in tumor size in animals treated with to Osimertinib, an epidermal growth factor tyrosine kinase inhibitor and anticancer therapeutic, was observed. A similar difference with combination of osimertinib+ and a second kinase inhibitor, FX9847, was also observed. However, when measured by the barcode sequencing method of the invention, a 12X and 24X difference was observed, respectively. It may be that an importantsource of the variability upon measurements of the primary tumor volumes with caliper is that it does not consider tumor necrosis, which could lead to significant underestimation of effects of drugs. However, measurements by barcoding detects only live tumor cells, which avoids counting necrotic cells and thus underestimation of drug effects. Thus, estimation of the drug effects with the barcoding system is significantly more accurate than by conventional methods.

[0068] Plotting the barcodes according to their presence in tumors or metastasis, i.e., size distribution of the barcoded clones, revealed novel and unexpected drug properties. It appears that some drugs, e.g., osimertinib, reduce the number of cancer cells in the population independently of their clonal origin, while other drugs, e.g., FX9847, kill some cancer clones and do not affect others.

[0069] Overall, the newly developed double barcoding system expands capabilities in studying tumor development and metastatic behavior of cancer cells and drug responses and can be of use both in research and patient care.

[0070] Further, the new libraries allow for improved methods of transcription factor and miR monitoring. The genetic screening makes use of the double barcoding to identify true hits (those that effect all cells in the same way) and false-positive hits (those that have only a clonal effect). It is the first barcode that makes this distinction possible and greatly improves the shRNA and CRISPR screens known in the art.

[0071] By a first aspect, there is provided a library of nucleic acid molecules, wherein a nucleic acid molecule of the library comprises a first barcode.

[0072] By another aspect, there is provided a library of virions wherein each virion comprises a nucleic acid molecule comprising a first barcode.

[0073] In some embodiments, the nucleic acid molecules further comprise a second barcode. In some embodiments, the first and second barcodes are different barcodes. In some embodiments, the first and second barcodes are the same length. In some embodiments, the first and second barcodes are the same length.

[0074] As used herein, the term "library" refers to a plurality of polynucleotide molecules which share common sequence surrounding unique or uncommon sequences or a plurality of enclosures each containing a polynucleotide molecule of a library. In some embodiments, the library is a library of plasmids. In some embodiments, the plasmids are vectors. In some embodiments, the unique or uncommon sequence in the molecules of the library is the first barcode. In some embodiments, the unique or uncommon sequence in the molecules of thelibrary is the second barcode. In some embodiments, the sequence of each molecule of the library is identical except for the sequence of the first barcode. In some embodiments, the sequence of each molecule of the library is identical except for the sequence of the first and second barcode.

[0075] In some embodiments, the library comprises at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 75, 80, 90, 100, 125, 150, 175, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, 5000, 10000, 20000, 25000, 50000, 75000, 80000, 100000, 200000, 300000, 400000, 500000, 600000, 700000, 800000, 900000, 1000000, 2000000, 3000000, 4000000, 5000000, 10000000, 20000000, 30000000, 40000000, 50000000, 60000000, 70000000, 80000000, 90000000 or 100000000 different nucleic acid molecules. Each possibility represents a separate embodiment of the invention. In some embodiments, the library comprises at least 1 thousand different nucleic acid molecules. In some embodiments, the library comprises at least 50 thousand different nucleic acid molecules. In some embodiments, the library comprises at least 200 thousand different nucleic acid molecules. In some embodiments, different nucleic acid molecules are different types of nucleic acid molecules. In some embodiments, a different type is a molecule comprising a different sequence.

[0076] In some embodiments, the nucleic acid molecule is an RNA. In some embodiments, the vector is an RNA vector. In some embodiments, the nucleic acid molecule is a DNA. In some embodiments, the vector is a DNA vector. The vector may be a DNA plasmid delivered via non-viral methods or via viral methods. In some embodiments, the vector is a viral vector. The viral vector may be a retroviral vector, a herpesviral vector, an adenoviral vector, an adeno-associated viral vector or a poxviral vector. In some embodiments, the viral vectors are selected from retroviral vectors, lentiviral vectors and adeno-associated viral vector.

[0077] In some embodiments, the vector is capable of integrating into a genome of a target cell. In some embodiments, the vector is capable of integrating the second barcode into a genome of a target cell. In some embodiments, the vector is capable of integrating the first barcode into a genome of a target cell. In some embodiments, the vector is capable of integrating the first and second barcodes into a genome of a target cell. In some embodiments, the vector is a viral vector. Viral vectors capable of genome integration are well known in the art and any such vector may be employed. In some embodiments, a target cell is a cell infected by a virus. In some embodiments, the virus is a virus comprising the viral vectors of the library. In some embodiments, the vector is configured for integration into a target cell. In some embodiments, the vector integrates the first and second barcodes. In some embodiments, thevector integrates the shRNA. In some embodiments, the vector integrates the gRNA. In some embodiments, the vector integrates the promoter.

[0078] In some embodiments, the viral vectors are retroviral vectors. In some embodiments, the viral vectors are lentiviral vectors. In some embodiments, viral vectors are adeno- associated viral vectors.

[0079] In some embodiments, the vector does not comprise an origin of replication. In some embodiments, the vector does not comprise an open reading frame. In some embodiments, the vector does not comprise a promoter. In some embodiments, the vector is not an expression vector. In some embodiments, the vector is devoid of an open reading frame. In some embodiments, the vector is devoid of a regulatory element configured for expression in a target cell. In some embodiments, the comprises a promoter. In some embodiments, the vector is an expression vector. In some embodiments, the vector comprises an origin of replication. In some embodiments, the vector comprises an open reading frame. In some embodiments, the promoter is configured for expression in a target cell.

[0080] Various methods can be used to introduce the expression vector of the present invention into cells. Such methods are generally described in Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Springs Harbor Laboratory, New York (1989, 1992), in Ausubel et al., Current Protocols in Molecular Biology, John Wiley and Sons, Baltimore, Md. (1989), Chang et al., Somatic Gene Therapy, CRC Press, Ann Arbor, Mich. (1995), Vega et al., Gene Targeting, CRC Press, Ann Arbor Mich. (1995), Vectors: A Survey of Molecular Cloning Vectors and Their Uses, Butterworths, Boston Mass. (1988) and Gilboa et at. [Biotechniques 4 (6): 504-512, 1986] and include, for example, stable or transient transfection, lipofection, electroporation and infection with recombinant viral vectors. In addition, see U.S. Pat. Nos. 5,464,764 and 5,487,992 for positive-negative selection methods. In some embodiments, the vector is introduced into the cell by standard methods including electroporation (e.g., as described in From et al., Proc. Natl. Acad. Sci. USA 82, 5824 (1985)), Heat shock, infection by viral vectors, high velocity ballistic penetration by small particles with the nucleic acid either within the matrix of small beads or particles, or on the surface (Klein et al., Nature 327. 70-73 (1987)), and / or the like.

[0081] In some embodiments, the library is a library of virions. In some embodiments, the library is a library of viruses. In some embodiments, virion is a viral particle. In some embodiments, each virion of the library comprises a nucleic acid molecule of the library of nucleic acid molecules. In some embodiments, the viral vectors of the library of viral vectorsare used to generate virus and the generated virus is a library of virions / viruses. In some embodiments, each virus of the library comprises a nucleic acid molecule of the library of nucleic acid molecules.

[0082] Methods of generating virus / virion libraries are well known in the art. The vector / plasmid library is transfected along with a virus coat packaging plasmid or other helper plasmid into a packaging cell line (e.g., 293LTX cells). The cells package each vector / plasmid into a virion that is secreted. The supernatant from the cells is collected and can be used directly for infection of target cells or the virus can be purified / concentrated and then used. The virus is provided to the target cells at a multiplicity of infection (MOI) that is sufficiently low such that on average each cell receives only one viral particle.

[0083] In some embodiments, the vector comprises a sequence of a short hairpin RNA (shRNA). In some embodiments, the sequence is a sequence that encodes the shRNA. In some embodiments, each vector comprises a sequence of an shRNA. As used herein, the term “shRNA” refers to single strand that forms a hairpin structure comprising a duplex region that can be cleaved into a small inhibitory / interfering RNA (siRNA). The term “siRNA” refers to small inhibitory RNA duplexes that induce the RNA interference (RNAi) pathway. As used herein, these molecules can vary in length (generally 17-30 base pairs plus overhangs) and contain varying degrees of complementarity to their target mRNA in the antisense strand. Some, but not all, siRNA have unpaired overhanging bases on the 5' or 3' end of the sense strand and / or the antisense strand. An shRNA is processed by DICER to produce the siRNA.

[0084] In some embodiments, the shRNA is specific to a target gene. In some embodiments, an shRNA knocks down a target gene. In some embodiments, knocks down comprises reducing expression of the target gene. In some embodiments, specific to a target gene comprises reverse complementarity to the target gene. In some embodiments, complementarity is at least 70, 75, 80, 85, 90, 92, 93, 95, 97, 99 or 100% complementarity. Each possibility represents a separate embodiment of the invention. It will be understood by a skilled artisan that an shRNA library, such as are well known in the art, can be modified to include the first and second barcode and thereby a library of the invention is produced. In some embodiments, an shRNA library is an RNAi library. shRNA libraries are commercially available and can be purchased from retailers such as Sigma- Aldrich, Horizon Discovery, and Cellecta to name but a few.

[0085] In some embodiments, the vector comprises a sequence of a CRISPR guide RNA (gRNA). In some embodiments, the sequence is a sequence that encodes the gRNA. In someembodiments, each vector comprises a sequence of a gRNA. Clustered Regularly Interspersed Short Palindromic Repeats (CRISPR) is a well-known method of producing DNA alterations. The CRISPR complex is targeted to a specific genomic sequence by a gRNA. The CRISPR / gRNA complex cuts around the target sequence and can either remove DNA or insert new DNA.

[0086] In some embodiments, the gRNA is specific to a target gene. In some embodiments, specific to is against. In some embodiments, an gRNA knocks down a target gene. In some embodiments, an gRNA knocks out a target gene. In some embodiments, knocks down comprises reducing expression of the target gene. In some embodiments, knocks out comprises rendering the target gene not expressed. In some embodiments, specific to a target gene comprises reverse complementarity to the target gene. In some embodiments, complementarity is at least 70, 75, 80, 85, 90, 92, 93, 95, 97, 99 or 100% complementarity. Each possibility represents a separate embodiment of the invention. It will be understood by a skilled artisan that a CRISPR library, such as are well known in the art, can be modified to include the first and second barcode and thereby a library of the invention is produced. In some embodiments, an CRISPR library is a gRNA library. CRISPR libraries are commercially available and can be purchased from retailers such as Addgene, Thermo Fisher, IDT, Horizon Discovery, Cellecta and GenScript to name but a few.

[0087] In some embodiments, a vector comprises a promoter. In some embodiments, the second barcode and first barcode are operably linked to the promoter. The term “operably linked” is intended to mean that the nucleotide sequence of interest (i.e., the barcodes) is linked to the regulatory element or elements (i.e., the promoter) in a manner that allows for expression of the nucleotide sequence (e.g., in a host cell when the vector is introduced into the host cell).

[0088] In some embodiments, the promoter is sufficient to drive transcription. In some embodiments, drive transcription is drive transcription in a target cell. In some embodiments, the promoter is an active promoter. In some embodiments, active is active in a target cell. In some embodiments, the promoter is a constitutive promoter. In some embodiments, a constitutive promoter is a constitutively active promoter. In some embodiments, the promoter is a strong promoter. In some embodiments, the promoter is the CMV promoter.

[0089] In some embodiments, the promoter comprises a minimal promoter. In some embodiments, the minimal promoter is CMV promoter. In some embodiments, the CMV promoter is a miniCMV promoter. Minimal promoters are well known in the art and any such promoter may be used.

[0090] In some embodiments, the promoter comprises at least one DNA-binding protein (DBP) binding site. In some embodiments, the binding site is specific to the DBP. In some embodiments, the at least one DBP binding is linked to the minimal promoter. In some embodiments, the DBP-binding site controls the minimal promoter. In some embodiments, transcription from the minimal promoter is dependent on DBP binding to the DBP binding site. In some embodiments, the promoter is configured to not produce transcription of operably linked sequence in the absence of DBP binding and to produce transcription of operably linked sequence in the presence of DBP binding. The library may comprise multiple different binding sites for the same DBP or may include only one binding stie for a DBP.

[0091] In some embodiments, the DBP is a transcription factor (TF). Transcription factors and their binding sites are well known in the art and any such sequences may be used. TF binding sites can be found for example in International Patent Application WO2018 / 169901 herein incorporated by reference in its entirety. The library may comprise multiple different binding sites for the same TF or may include only one binding stie for a TF.

[0092] In some embodiments, the DBP is a component of a DNA-modification complex. In some embodiments, the DBP modifies DNA. In some embodiments, the DBP is a DNA modification binder. In some embodiments, the DBP is a component of a histone biding complex. In some embodiments, the DBP binds a histone. In some embodiments, a histone binding complex is a histone modifying complex. In some embodiments, the DBP is a histone binding protein.

[0093] In some embodiments, each vector comprises a transcribed region. In some embodiments, a transcribed region is a transcribable region. In some embodiments, each vector comprises a region downstream of the promoter that is operably linked to the promoter. In some embodiments, the region is configured such that the promoter drives transcription of the region. In some embodiments, the region is transcribable. In some embodiments, the region comprises an open reading frame. In some embodiments, the region comprises a coding region. In some embodiments, the region encodes a protein. In some embodiments, each vector comprises an open reading frame. In some embodiments, each vector comprises a coding sequence. In some embodiments, the coding sequence encodes a protein. In some embodiments, the open reading frame encodes a protein. In some embodiments, the promoter is operably linked to the open reading frame. In some embodiments, the promoter is operably linked to the coding sequence. In some embodiments, the vector is configured so that the promoter drives transcription of an mRNA. In some embodiments, the vector is configured so that the promoter transcribes an mRNA encoding the protein. In some embodiments, themRNA encodes a protein. In some embodiments, the open reading frame comprises introns. In some embodiments, the open reading frame is devoid of introns. In some embodiments, the open reading frame comprises the coding sequence. In some embodiments, the open reading frame comprises the coding sequence and introns.

[0094] In some embodiments, the protein is a reporter protein. In some embodiments, the protein is a fluorescent protein. In some embodiments, the protein is a fluorescent reporter. Examples of fluorescent reporters include, but are not limited to GFP, eGFP, mCherry, RFP, YFP, BFP and the like. In some embodiments, the protein is GFP.

[0095] In some embodiments, the protein is a short protein. In some embodiments, a short protein comprises at most 100, 200, 250, 300, 400, 500, 600, 700, 750, 800, 900 or 1000 amino acids. Each possibility represents a separate embodiment of the invention. In some embodiments, the coding region is a short coding region. In some embodiments, a short coding region comprises at most 100, 200, 250, 300, 400, 500, 600, 750, 800, 900, 1000, 1100, 1200, 1250, 1300, 1400, 1500, 1600, 1700, 1750, 1800, 1900, 2000, 2100, 2200, 2250, 2300, 2400, 2500, 2600, 2700, 2750, 2800, 2900 or 3000 nucleotides. Each possibility represents a separate embodiment of the invention.

[0096] In some embodiments, each vector comprises a microRNA (miR) binding site. In some embodiments, the promoter is operably linked to the miR binding site. In some embodiments, the vector is configured so that the promoter transcribes the miR binding site. In some embodiments, the miR binding site is in the coding sequence. In some embodiments, the miR binding site is in the open reading frame. In some embodiments, the miR binding site is within an intron. In some embodiments, each vector further comprises an untranslated region (UTR). In some embodiments, the UTR is a 3’ UTR. In some embodiments, the UTR is a 5’ UTR. In some embodiments, the UTR is 3’ to the coding region. In some embodiments, the UTR is after the coding region. In some embodiments, the 3’ UTR is directly after the stop codon. In some embodiments, the 5’ UTR is directly before the start codon. In some embodiments, the miR binding site is within the 3’ UTR. In some embodiments, the miR binding site is within the 5’ UTR.

[0097] In some embodiments, the miR binding site is 5’ to the first barcode. In some embodiments, the miR binding she is 3’ to the first barcode. In some embodiments, the miR binding site is 5’ to the second barcode. In some embodiments, the miR binding she is 3’ to the second barcode. In some embodiments, the first barcode is in a UTR. In someembodiments, the second barcode is in a UTR. In some embodiments, the first barcode is in the 3’ UTR. In some embodiments, the second barcode is in the 3’ UTR.

[0098] In some embodiments, the library comprises a plurality of vectors with the same miR binding site. In some embodiments, the library comprises a plurality of vectors with binding sites for the same miR. In some embodiments, each vector of the plurality comprises a unique first barcode. In some embodiments, each vector of the plurality comprises the same second barcode. In some embodiments, the second barcode is unique to the miR. In some embodiments, the second barcode is unique to the miR binding site. In some embodiments, a plurality of vectors with the same miR binding site comprises vectors with the same second nucleic acid barcode. In some embodiments, a plurality of vectors with binding sites for the same miR comprises vectors with the same second nucleic acid barcode.

[0099] In some embodiments, the library comprises a plurality of vectors with sequence comprising a binding site for a first miR of a plurality of miRs and a plurality of vectors with sequence comprising biding sites for a second miR of a plurality of miRs. In some embodiments, the library comprises a plurality of vectors with transcribable sequence comprising a binding site for a first miR of a plurality of miRs and a plurality of vectors with transcribable sequence comprising biding sites for a second miR of a plurality of miRs. In some embodiments, the library comprises a plurality of vectors with binding sites to each miR of a plurality of miRs. A skilled artisan will understand that a library will have binding sites for many miRs so that all of the miRs can be targeted in the same experiments. In such cases, each unique miR binding site sequence will also have many vectors with that same sequence because each of those vectors will have a different first barcode.

[0100] In some embodiments, the library comprises a plurality of vectors with the same sequence of an shRNA. In some embodiments, the library comprises a plurality of vectors with the same sequence of a gRNA. In some embodiments, the library comprises a plurality of vectors with the same DBP binding site. In some embodiments, all vectors with the same sequence of a shRNA comprise the same second barcode. In some embodiments, all vectors with the same sequence of a gRNA comprise the same second barcode. In some embodiments, all vectors with the same sequence of a DBP binding site comprise the same second barcode. In some embodiments, the second barcode is unique to the shRNA. In some embodiments, the second barcode is unique to the gRNA. In some embodiments, the second barcode is unique to the DBP binding site. In some embodiments, the second barcode is unique to the DBP. In some embodiments, unique to is uniquely identifies. It will be understood by a skilled artisan that each shRNA, gRNA or DBP binding site sequence will be associated with a particularsecond barcode sequence. The presence of that second barcode sequence in a cell indicates that its associated shRNA or gRNA is also expressed in the cell or that the cell comprises the promoter with the associated DBP binding site promoter.

[0101] In some embodiments, each vector of the plurality of vectors comprises a unique first barcode. In some embodiments, unique is different. It will be understood by a skilled artisan that while all vectors containing the same shRNA, gRNA, DBP binding site, miR binding site will also contain the same second barcode they will also each have a distinct / different / unique first barcode. Thus, there will be only one copy of a vector with any particular combination of first and second barcodes. In this way, each vector can be uniquely identified based on the combination of first and second barcodes.

[0102] In some embodiments, the library comprises vectors with shRNA sequences specific to a plurality of genes. In some embodiments, the library comprises vectors with gRNA sequences specific a plurality of genes. In some embodiments, the library comprises vectors with promoters comprising binding sites to a plurality of DBPs. In some embodiments, the genes of the plurality are different genes. In some embodiments, the DBPs of the plurality are different DBPs. In some embodiments, the library comprises vectors with shRNA sequences specific to all annotated genes in a genome. In some embodiments, the library comprises vectors with gRNA sequences specific to all annotated genes in a genome. In some embodiments, the library comprises a plurality of vectors with shRNA sequences specific to a first gene of a plurality of genes and a plurality of vectors with shRNA sequences specific to a second gene of a plurality of genes. In some embodiments, the library comprises a plurality of vectors with shRNA sequences specific to each gene of a plurality of genes. In some embodiments, the library comprises a plurality of vectors with gRNA sequences specific to a first gene of a plurality of genes and a plurality of vectors with gRNA sequences specific to a second gene of a plurality of genes. In some embodiments, the library comprises a plurality of vectors with gRNA sequences specific to each gene of a plurality of genes. In some embodiments, the library comprises a plurality of vectors with promoters comprising binding site for a first DBP of a plurality of DBPs and a plurality of vectors with promoters comprising biding sites for a second DBP of a plurality of DBPs. In some embodiments, the library comprises a plurality of vectors with promoters comprising binding sites to each DBP of a plurality of DBPs. A skilled artisan will understand that a library will have shRNA sequences or gRNA sequences against many genes so that all of the genes can be targeted in the same experiments. In such cases, each unique shRNA or gRNA sequence will also have many vectors with that same sequence because each of those vectors will have a different firstbarcode. Similarly, a library will have promoters with binding sites for many DBPs or many different binding sites for a DBP so that all DBPs can be investigated in the same experiment. In such cases, each unique DBP binding site will also have many vectors with the same sequence because each of those vectors will have a different first barcode.

[0103] In some embodiments, a plurality is at least two. In some embodiments, a plurality is at least 5. In some embodiments, a plurality is at least 10. In some embodiments, a plurality is at least 100. In some embodiments, a plurality is at least 500. In some embodiments, a plurality is at least 1000. In some embodiments, a plurality is at least 2000. In some embodiments, a plurality is at least 3000. In some embodiments, a plurality is at least 10000. In some embodiments, a plurality is at least 15000. In some embodiments, a plurality is at least 2, 3, 5, 7, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 11000, 12000, 13000, 14000 or 15000. Each possibility represents a separate embodiment of the invention.

[0104] In some embodiments, each nucleic acid molecule of the library comprises a first barcode. In some embodiments, each nucleic acid molecule of the library comprises a first barcode and a second barcode. As used throughout the invention "barcode", and "nucleic acid barcode", are interchangeable with each other and have the same meaning. These terms refer to a nucleotide sequence which identifies a nucleic acid molecule, or a virion, cell or other area that contains the nucleic acid molecule comprising the barcode. The nucleic acid molecule serving as a barcode is a polymer of nucleic acids and may be single-stranded or doublestranded, optionally containing synthetic, non-natural or altered nucleotide bases. The presence of the barcode, that is the barcode’s detection, indicates the presence of the nucleic acid molecule that contains the barcode. When the barcode is integrated into a cell’s genome the barcode is a barcode for the cell and the cell and its descendants can be identified by the barcode. In some embodiments, cells comprising the first and second barcode are doublebarcoded cells.

[0105] In some embodiments, the nucleic acid molecule comprises or consists of a pre-defined unique sequence. As used herein, the term "unique sequence" or "uniquely identifying" refers to a sequence based on an injective function (also termed one-to-one function) that preserves distinctness. In some embodiments, the barcode is the unique sequence. A unique barcode (e.g., a nucleic acid having a unique sequence) is suitable for identifying a cell and its descendants after implementing the methods of the invention. In some embodiments, the unique sequence is a predefined sequence. In some embodiments, the unique sequence is aknown sequence. In some embodiment, the molecules of the library are identical except for the unique sequence. In some embodiments, molecules with the same promoter are identical except for the unique sequence. In some embodiments, molecules with the same sequence of an shRNA or gRNA are identical except for the unique sequence. In some embodiments, the unique sequence is both the first and second barcode. In some embodiments, the unique sequence is the first barcode.

[0106] The term "nucleic acid" is well known in the art. A "nucleic acid" as used herein will generally refer to a molecule (i.e., a strand) of DNA, RNA or a derivative or analog thereof, comprising a nucleobase. A nucleobase includes, for example, a naturally occurring purine or pyrimidine base found in DNA (e.g., an adenine "A," a guanine "G," a thymine "T" or a cytosine "C") or RNA (e.g., an A, a G, an uracil "U" or a C). Other examples of nucleic acids include for example, peptide nucleic acids (PNA), locked nucleic acids (LNA) and bridged nucleic acids (BNA). In some embodiments, the nucleic acid is DNA or a derivative thereof.

[0107] The term “nucleic acid molecule” includes but is not limited to single-stranded RNA (ssRNA), double-stranded RNA (dsRNA), single -stranded DNA (ssDNA), double- stranded DNA (dsDNA), PNA, LNA and artificial nucleic acids such as oligonucleotides. In some embodiments, the nucleic acid molecule is a DNA molecule. In some embodiments, the nucleic acid molecule is a vector. In some embodiments, the vector is an expression vector. In some embodiments, the vector is a viral vector.

[0108] The term “microRNA” and “miR” are synonymous and used interchangeably. These terms refer to very small, non-coding RNA molecules that are involved in the regulation of gene expression. Specifically, miR binding is known to inhibit mRNA translation and to cause mRNA instability and degradation. MicroRNAs are transcribed by RNA polymerases II and III, generating precursors that undergo a series of cleavage events to form mature microRNA. The sequences of miRs are well known and can be found at available databases such as miRbase, MiRTarBase, miRGeneDB and the like. In some embodiments, the miR binding stie is reverse complementary to a miR.

[0109] In some embodiment, the barcode is one or more nucleic acid molecules. In some embodiments, the barcode is a nucleic acid barcode. In some embodiments, the barcode is a DNA barcode. In some embodiments, the barcode is an RNA barcode. In some embodiments, the barcode comprises a unique sequence. In some embodiments, the unique sequence is not found in nature. In some embodiments, the unique sequence is not found in a genome of a target cell. In some embodiments, the target cell is a eukaryotic cell. In some embodiments,the target cell is a prokaryotic cell. In some embodiments, the target cell is a bacterial cell. In some embodiments, the target cell is a mammalian cell. In some embodiments, the target cell is a yeast cell. In some embodiments, the target cell is a rodent cell. In some embodiments, the target cell is a human cell. In some embodiments, the target cell is a cell in a target organism. In some embodiments, the organism is the subject. In some embodiments, the barcode is not in an open reading frame. In some embodiments, the barcode is not a part of a protein coding sequence. In some embodiments, the barcode is not part of a regulatory element. In some embodiments, the barcode is not part of a regulatory sequence. In some embodiments, the barcode is operatively linked to the promoter. Examples of barcodes that can be used as part of the method of the invention are provided hereinbelow, though libraries of barcodes that can be used are known in the art and randomly generated barcodes may also be used. Technologies for producing randomly generated barcodes are well known in the art.

[0110] In some embodiments, the sequence of the nucleic acid molecule is exclusive of sequences, patterns, signatures or any other nucleic acid sequences associated with a material / substance / particle that is naturally occurring in the environment or particularly naturally occurring in the cell being targeted by the methods of the invention. In some embodiments, the sequence of the nucleic acid barcode is devoid of a nucleotide sequence of 8 or more bases which can associate with a naturally occurring nucleotide sequence. In some embodiments, the sequence of the nucleic acid barcode is devoid of a nucleotide sequence of 8 or more bases which is identical to a naturally occurring sequence. In some embodiments, the sequence of the nucleic acid barcode is devoid of a nucleotide sequence of 8 or more bases which is identical to a sequence in a genome of a target cell. In some embodiments, the sequence of the nucleic acid barcode is devoid of a nucleotide sequence of 8 or more bases which is complementary to a naturally occurring sequence. In some embodiments, the sequence of the nucleic acid barcode is devoid of a nucleotide sequence of 8 or more bases which is complementary to a sequence in a genome of a target cell. In some embodiments, complementary is perfectly complementary. In some embodiments, complementary is at least 70, 75, 80, 85, 90, 95, 97, 99 or 100% complementary. Each possibility represents a separate embodiment of the invention. In another embodiment, the nucleic acid molecule comprises a sequence which is not substantially identical or complementary to the target cell's genomic material (such as to prevent hybridization of the nucleic acid molecule with the cell's genomic material, particularly of the cell's exons and / or prevent false positive amplification results).

[0111] Methods for the detection of the presence and identification of a nucleic acid sequence are known to a skilled artisan and include sequencing, next generation sequencing (NGS),PCR, quantitative PCR (qPCR) and array (e.g., microarray) systems capable of detecting the presence of multiple barcodes (e.g., commercially available by Ilumina Inc.).

[0112] In some embodiments, the barcode is a short sequence. In some embodiments, the barcode comprises a length of at most 8, 10, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 60, 70, 75, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900 or 1000 nucleotides. Each possibility represents a separate embodiment of the invention. In some embodiments, the barcode comprises a length of at most 12 nucleotides. In some embodiments, the barcode comprises a length of at most 14 nucleotides. In some embodiments, the barcode comprises a length of at most 20 nucleotides. In some embodiments, the barcode comprises a length of at least 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 nucleotides. Each possibility represents a separate embodiment of the invention. In some embodiments, the barcode comprises a length of at least 1 nucleotide. In some embodiments, the barcode comprises a length of at least 2 nucleotides. In some embodiments, the barcode comprises a length of at least 8 nucleotides. In some embodiments, the barcode comprises a length of at least 10 nucleotides. In some embodiments, the barcode comprises a length of 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16 nucleotides. Each possibility represents a separate embodiment of the invention. In some embodiments, the barcode comprises a length of 8 nucleotides. In some embodiments, the barcode comprises a length of 10 nucleotides. In some embodiments, the barcode comprises a length of 12 nucleotides. In some embodiments, the second barcode is 8 nucleotides in length. In some embodiments, the first barcode is 12 nucleotides in length. In some embodiments, the barcode comprises between 6-16, 6-14, 6-12, 8-16, 8-14, or 8-12 nucleotides. Each possibility represents a separate embodiment of the invention. In some embodiments, the barcode comprises 8-14 nucleotides. In some embodiments, the barcode comprises 8-12 nucleotides.

[0113] In some embodiments, a library comprises a third barcode. In some embodiments, each vector of a library comprises a third barcode. In some embodiments, the third barcode is common to all molecules of the library. In some embodiments, the third barcode is a libraryspecific barcode. In some embodiments, the library is a first library of a plurality of libraries. In some embodiments, the third barcode identifies molecules of the library. In some embodiments, the third barcode identifies virions of the library. In some embodiments, the third barcode identifies virus of the library. In some embodiments, the third barcode is for use in identifying the library. In some embodiments, the third barcode is for use in distinguishing the library from another library. In some embodiments, the library is a first library, and the firsts barcode is for use in identifying or distinguishing the first library.

[0114] In some embodiments, the first barcode is unique to each nucleic acid molecule of the library. In some embodiments, the first barcode is unique to each type of nucleic acid molecule of the library. In some embodiments, the first barcode is unique to each virion of the library. In some embodiments, the first barcode is unique to each virus of the library. In some embodiments, a unique barcode is non-redundant in the library. In some embodiments, the first barcode is a molecule-specific barcode. In some embodiments, the first barcode is a virionspecific barcode. In some embodiments, the first barcode is for use in identifying a specific molecule of the library. In some embodiments, the first barcode is for use in distinguishing a specific molecule of the library from the other molecules of the library. In some embodiments, the first barcode is for use in distinguishing / identifying a cell infected by a specific molecule or virion of the library. In some embodiments, the first barcode is a cell-specific barcode. In some embodiments, a cell is a cell and its descendants. As used herein, a “descendant” refers to any cell that results from cellular division from an original cell. A descendant will therefore share the same genome as the parent cell. Since the barcodes will integrate into the genome of cells they infect, the barcodes will be passed on to descendant cells. Further, because each genome will only contain one copy of the barcode the number of barcodes will be directly proportional to the number of cells with the barcode.

[0115] In some embodiments, the first barcode is a randomly generated sequence. Methods of generating barcode sequences are well known in the art and any such method may be used. One such method is provided hereinbelow. Representative barcode sequences both for the first and second barcodes can also be found hereinbelow. It will be understood by a skilled artisan that nearly any sequence can potentially be used as a barcode so long as it can be uniquely detected. When sequencing is performed, the molecule with sequence information will include both the first and second barcode. Therefore, so long as these two sequences together are not found in nature or the target cell, a sequencing read with both sequences will have to have come from the barcode and not some other source. In some embodiments, the library has been sequenced. In some embodiments, the method comprises sequencing the library. In some embodiments, sequencing is deep sequencing. In some embodiments, sequencing is next generation sequencing. In some embodiments, sequencing is massively parallel sequencing. In some embodiments, all vectors of the library have been sequenced. In some embodiments, the library has been sequenced such that the DNA-binding protein binding site and the randomly generated sequence of each vector is known. In some embodiments, the library has been sequenced such that the DNA-binding protein binding site and the randomly generated sequence of each vector is identified. In some embodiments, the library has been sequencedsuch that the DNA-binding protein binding site and the sequence of the first barcode of each vector is known. In some embodiments, the library has been sequenced such that the DNA- binding protein binding site and the sequence of the first barcode of each vector is identified. In some embodiments, the DNA-binding protein binding site and the randomly generated sequence of each vector is known. In some embodiments, the DNA-binding protein binding site and the randomly generated sequence of each vector is identified. In some embodiments, the DNA-binding protein binding site and the sequence of the first barcode of each vector is known. In some embodiments, the DNA-binding protein binding site and the sequence of the first barcode of each vector is identified. A skilled artisan will appreciate that if all first barcodes on all vectors comprising a given binding stie are known that the summing of all those first barcodes is equivalent to all second barcodes identifying that binding site.

[0116] In some embodiments, a DBP binding site is at least one DBP binding site. In some embodiments, a DBP binding site is a repeat DBP binding site. In some embodiments, a repeat is at least two copies of the DBP binding site. In some embodiments, a repeat is at least 2, 3, 4, 5, 6, 7, 8, 9 or 10 repeats of the DBP binding site. Each possibility represents a separate embodiment of the invention. In some embodiments, a repeat is 2 copies. In some embodiments, a repeat is 3 copies. In some embodiments, a repeat is 4 copies.

[0117] In some embodiments, a miR binding site is at least one MIR binding site. In some embodiments, a MIR binding site is a repeat MIR binding site. In some embodiments, a repeat is at least two copies of the MIR binding site. In some embodiments, a repeat is at least 2, 3, 4, 5, 6, 7, 8, 9 or 10 repeats of the MIR binding site. Each possibility represents a separate embodiment of the invention. In some embodiments, a repeat is 2 copies. In some embodiments, a repeat is 3 copies. In some embodiments, a repeat is 4 copies.

[0118] In some embodiments, the second barcode is 5’ to the first barcode. In some embodiments, the second barcode is upstream to the first barcode. In some embodiments, the first barcode is 5’ to the second barcode. In some embodiments, the first barcode is upstream to the second barcode. In some embodiments, the second barcode is 3’ to the first barcode. In some embodiments, the second barcode is downstream to the first barcode. In some embodiments, the first barcode is 3’ to the second barcode. In some embodiments, the first barcode is downstream to the second barcode.

[0119] In some embodiments, the second barcode and the first barcode are separated by a spacer. In some embodiments, the spacer comprises at least 1 nucleotide. In some embodiments, the spacer comprises at most 1000 nucleotides. In some embodiments, thespacer is small enough to allow the first and second barcodes to be in a single sequencing read. Depending on the sequencing technology employed and the specific sequencer the average size of the reads will change. The size of the spacer therefore can also change but must not be so large that the first and second barcodes tend to end up in separate reads. Generally, the spacer will be small so as to increase the chances that the first and second barcodes are in the same sequencing read. In some embodiments, the spacer is sufficiently small such that the second barcode and first barcode can both be sequenced in one sequencing read. In some embodiments, the spacer is sufficiently small such that the second barcode and the first barcode will both be in the same nucleic acid molecule after fractionation. In some embodiments, the spacer is sufficiently small such that the second barcode and the first barcode will both be in the same nucleic acid molecule after amplification. It will be understood by a skilled artisan that when sequencing a sample with nucleic acid molecules, those molecules must be labelled with adapters and generally are amplified before sequencing. To facilitate this the sample nucleic acids can be fragmented into smaller pieces of about 300 nucleotides (250-350 on average). Alternatively, and as exemplified hereinbelow, target sequences (i.e., the viral sequences containing the barcodes) can be specifically amplified and the amplification product can have adapters added for sequencing. In some embodiments, the amplification is nested amplification. So, the first and second barcodes should not be so separated as to one fit on a single fragmented molecule or single amplicon.

[0120] In some embodiments, the barcodes are 5’ to the shRNA or gRNA. In some embodiments, the barcodes are 3’ to the shRNA or gRNA. In some embodiments, the barcodes are configured such that CRISPR excision via the gRNA integrates the barcodes into the target DNA. In some embodiments, the target RNA is the genome of a cell. In some embodiments, the spacer is cleavable such that the shRNA or gRNA are in separate molecules from the barcodes. In some embodiments, the shRNA or gRNA are in separate transcripts from the barcodes. In some embodiments, a P2A, T2A, E2A or F2A sequence is present between the shRNA or gRNA and the barcodes. In some embodiments, an IRES sequence is present between the shRNA or gRNA and the barcodes.

[0121] By another aspect, there is provided a kit comprising at least two libraries of the invention.

[0122] In some embodiments, at least two is a plurality. In some embodiments, each of the at least two libraries further comprise a third nucleic acid barcode. In some embodiments, the third barcode identifies the library. In some embodiments, first library comprises a different third nucleic acid barcode from a third nucleic acid barcode of a second library. In someembodiments, each library of the kit comprises a unique third barcode. In some embodiments, each vector of a library comprises the same third barcode.

[0123] In some embodiments, the plurality comprises a first library and a second library. In some embodiments, the plurality is at least two libraries. In some embodiments, the plurality is at least 2, 3, 4, 5, 6, 7, 8, 9 or 10 libraries. Each possibility represents a separate embodiment of the invention. In some embodiments, the second barcode is a library- specific barcode. In some embodiments, the second barcode of the first library is different from the second barcode of the second library. In some embodiments, the second barcode of a library of the plurality of libraries is different from every other second barcode of over other library of the plurality of libraries. It will be understood, that when two libraries are used together in the same experiment, they can be distinguished by their second barcodes. Thus, even if the first barcodes are redundant between the libraries, the molecules of the library can all be uniquely tracked as the second barcode identifies the library and the first barcode identifies the unique molecule within the library.

[0124] In some embodiments, the first library and the second library comprise the same first barcodes. In some embodiments, the first library and the second library comprise the same second barcodes. In some embodiments, the first library and second library are the same except for the third barcode. In some embodiments, the same is identical. In some embodiments, the libraries of the plurality all comprise the same first barcodes. In some embodiments, the libraries of the plurality all comprise the same second barcodes. In some embodiments, the libraries of the plurality are all the same except for the third barcode.

[0125] In some embodiments, the kit further comprises at least one helper plasmid. In some embodiments, the helper plasmid is a virus coat packaging plasmid. In some embodiments, the helper plasmid comprises at least one open reading frame. In some embodiments, the open reading frame encodes at least one viral protein. In some embodiments, the viral protein is a structural protein. In some embodiments, the viral protein is a coat protein. In some embodiments, the coat protein is a capsid. In some embodiments, the viral protein is a protein required for production of virus. In some embodiments, the viral protein is a protein required for production of viral particles. In some embodiments, the virus is infection-competent virus. In some embodiments, the helper plasmid comprises an open reading frame for all the viral proteins required to produce virus that can integrate the barcodes into the genome of a target cell.

[0126] By another aspect, there is provided a method of cellular tracking, the method comprising: a. infecting a first population of cells with a first viral library to produce a first double-barcoded population; b. infecting a second population of cells with a second viral library to produce a second double -barcoded population; c. administering the first double-barcoded population and the second doublebarcoded population to a subject; and d. tracking a cell and / or a descendant of a cell from the first population or second population in the subject by identifying a nucleic acid molecule comprising a second nucleic acid barcode and a first nucleic acid barcode; thereby tracking a cell.

[0127] By another aspect, there is provided a method of cellular tracking, the method comprising: a. infecting a first population of cells with a first viral library to produce a first double-barcoded population; b. infecting a second population of cells with a second viral library to produce a second double -barcoded population; c. mixing the first double-barcoded population and the second double-barcoded population to produce a cellular mixture; and d. tracking a cell and / or a descendant of a cell from the first population or second population in the cellular mixture by identifying a nucleic acid molecule comprising a second nucleic acid barcode and a first nucleic acid barcode; thereby tracking a cell.

[0128] By another aspect, there is provided a method of labelling a population of cells, the method comprising contacting a population of cells with a library of the invention, thereby labelling the population of cells.

[0129] By another aspect, there is provided a method of genetic screening, the method comprising:a. contacting a population of cells with a library of the invention to produce a barcoded population of cells; b. selecting cells from the barcoded population of cells with a target phenotype; and c. identifying sequences of first barcodes within the selected cells; thereby performing genetic screening.

[0130] By another aspect, there is provided a method of genetic screening, the method comprising: a. contacting a population of cells with a library of the invention to produce a barcoded population of cells; b. selecting cells from the barcoded population of cells with a target phenotype; and c. identifying sequences of first and second barcodes on the same nucleic acid molecule within the selected cells; thereby performing genetic screening.

[0131] By another aspect, there is provided a method comprising: a. contacting a population of cells with a library of the invention to produce a barcoded population of cells; and b. identifying sequences of first and second barcodes on the same nucleic acid molecule within the double-barcoded population.

[0132] By another aspect, there is provided a method comprising: a. contacting a population of cells with a library of the invention to produce a barcoded population of cells; and b. identifying sequences of first barcodes within the double -barcoded population.

[0133] In some embodiments, contacting comprises infecting. In some embodiments, the vectors are viral vectors and the contacting comprises infecting the population with the library. In some embodiments, infecting results in integration of the barcodes into the population of cells. In some embodiments, infecting results in integration of the shRNA or gRNA into the population of cells. In some embodiments, infecting results in integration of the promoter intothe population of cells. In some embodiments, infecting results in integration of the vector into the population of cells.

[0134] In some embodiments, a barcoded population is a double -barcoded population. In some embodiments, the method further comprises growing the barcoded population. In some embodiments, growing is culturing. In some embodiments, the culturing is for a sufficient time for the appearance of cells with a target phenotype. In some embodiments, the method is a method of screening for a target phenotype. In some embodiments, the method is a method of genetic screening to determine a gene whose reduced expression produces the target phenotype. In some embodiments, reduces expression is knockdown. In some embodiments, reduced expression is absence of expression. In some embodiments, reduced expression is knockout. In some embodiments, reduced expression is mutation of. In some embodiments, the target phenotype is survival. In some embodiments, the time is sufficient for death of some cells and survival of others.

[0135] In some embodiments, the method further comprises contacting the population of cells with a test condition. In some embodiments, the method further comprises contacting the population of cells with a test condition prior to contacting with a library. In some embodiments, the method further comprises contacting the barcoded population with a test condition. In some embodiments, the test condition is administered. IN some embodiments, the test condition is before the selecting. In some embodiments, the test condition is before the growing. In some embodiments, the test condition is a stressor. In some embodiments, the test condition is an environmental condition. Environmental conditions such as hypoxia, low glucose, ER stress, salt stress, coincubation with other cells or administration to a subject are all well known in the art, and all may be tested.

[0136] In some embodiments, the test condition comprises contacting the barcoded population with a therapeutic agent. In some embodiments, the therapeutic agent is a drug. In some embodiments, the method is a method of screening for drug resistance. In some embodiments, the method is method of screening for drug susceptibility. In some embodiments, the agent is a cytotoxic agent. In some embodiments, the drug is an anticancer agent. In some embodiments, the agent is a chemotherapy. In some embodiments, the agent is a combination of agents. In some embodiments, the target phenotype is cell survival. In some embodiments, the target phenotype is cell growth. In some embodiments, a single cell lethal dose of the agent is administered. In some embodiments, the agent is administered at a dose sufficient to kill the population of cells. In some embodiments, the population of cells is the population before contact with the library.

[0137] In some embodiments, the method is a method of measuring activity of at least one transcription factor. In some embodiments, the method is a method of measuring activity of at least two transcription factors. In some embodiments, activity is activity in a population of cells. In some embodiments, measuring activity is in vivo activity. In some embodiments, activity is activity in a primary tumor. In some embodiments, activity is activity in a cancer metastasis. In some embodiments, measuring is simultaneously measuring. In some embodiments, the amount of a first second barcode is proportional to the activity of a first transcription factor. In some embodiments, the first second barcode is associated with the first DBP. In some embodiments, a binding site of the first DBP is part of the promoter operably linked to the first second barcode. In some embodiments, a second second barcode is proportional to the activity of a second DBP. In some embodiments, a binding site of the second DBP is part of the promoter operably linked to the second second barcode. In some embodiments, the amount of each second barcode is proportional to the activity of the DBP associated with that second barcode. In some embodiments, the amount of each second barcode is proportional to the activity of the DBP whose binding site is in the promoter operably linked to each second barcode. In some embodiments, the amount of all first barcodes known to be on vectors comprising a first DNA-binding protein binding site is proportional to the activity of a first DBP. In some embodiments, the amount of all second first barcodes known to be on vectors comprising a second DNA-binding protein binding site is proportional to the activity of a second DBP. In some embodiments, the activity of a DBP is proportional to the amount of all first barcodes known to be on vectors comprising that DBP’s binding site. In some embodiments, a DBP is a transcription factor. In some embodiments, a transcription factor is a DBP.

[0138] In some embodiments, the method is a method of measuring activity of at least one miR. In some embodiments, the method is a method of measuring activity of at least two miRs. In some embodiments, activity is activity in a population of cells. In some embodiments, measuring activity is in vivo activity. In some embodiments, activity is activity in a primary tumor. In some embodiments, activity is activity in a cancer metastasis. In some embodiments, measuring is simultaneously measuring. In some embodiments, the amount of a first second barcode is inversely proportional to the activity of a first miR. In some embodiments, the first second barcode is associated with the first miR. In some embodiments, a second second barcode is inversely proportional to the activity of a second miR. In some embodiments, a binding site of the second miR is part of the promoter operably linked to the second second barcode. In some embodiments, the amount of each second barcode is inversely proportionalto the activity of the miR associated with that second barcode. In some embodiments, the amount of each second barcode is inversely proportional to the activity of the miR whose binding site is in the promoter operably linked to each second barcode. In some embodiments, the amount of all first barcodes known to be on vectors comprising a first miR binding site is inversely proportional to the activity of a first miR. In some embodiments, the amount of all second first barcodes known to be on vectors comprising a second miR binding site is inversely proportional to the activity of a second miR. In some embodiments, the activity of a miR is inversely proportional to the amount of all first barcodes known to be on vectors comprising that miR’s binding site.

[0139] In some embodiments, the method is a method of tracking a cell in a subject. In some embodiments, the method is a method of tracking at least one cell. In some embodiments, the method is a method of tracking a plurality of cells. In some embodiments, the method is a method of tracking cells from two different populations. In some embodiments, the method is a method of tracking cells from a plurality of different populations. In some embodiments, the method is a method of simultaneously tracking two different cells. In some embodiments, two different cells are from different populations. In some embodiments, the two different cells are from the same population.

[0140] In some embodiments, the subject is a mammal. In some embodiments, the subject is a rodent. In some embodiments, the rodent is a mouse. In some embodiments, the subject is a lab animal. In some embodiments, the subject is a human. In some embodiments, the subject is not a human. In some embodiments, the subject is a non-human subject. In some embodiments, the method is method performed outside of a human body. In some embodiments, the population of cells are administered to a non-human subject. In some embodiments, the method is a method of in vivo measurement.

[0141] In some embodiments, the first population of cells, the second population of cells or both are disease cells. In some embodiments, the disease is cancer. In some embodiments, the first population of cells are disease cells and the second population are healthy cells. In some embodiments, both the first population of cells and the second population of cells are disease cells. In some embodiments, the first and second populations are cells of the same disease.

[0142] In some embodiments, the first population of cells is from a patient. In some embodiments, the patient is a subject. In some embodiments, the patient is a human. In some embodiments, the first population are disease cells from a patient. In some embodiments, the first population of cells are cancer cells from a patient. In some embodiments, the method is amethod of tracking cells in a patient-derived xenograft (PDX). In some embodiments, the method is a method of measuring metastasis of a PDX. In some embodiments, the method is a method of monitoring a PDX. In some embodiments, the method is a method of testing a therapeutic agent on a PDX. In some embodiments, the method is a method of monitoring the effect of a therapeutic agent on a PDX.

[0143] In some embodiments, the first library is a library of the invention. In some embodiments, second library is a library of the invention. In some embodiments, the infecting results in integration of the library into the genome of the cells of the population. In some embodiments, the infecting results in the integration of the first and second barcodes into the genome of the cells of the population. In some embodiments, infecting results in integration of the second barcode and the first barcode of the first library into cells of the first population. In some embodiments, infecting results in integration of the second barcode and the first barcode of the second library into cells of the second population. In some embodiments, the infection results in the integration of 1 nucleic acid molecule of the library into a genome of a cell of the population. In some embodiments, the infection results in the integration of at most 1 nucleic acid molecule of the library into a genome of a cell of the population. In some embodiments, the infection results in 1 second barcode and 1 first barcode being integrated into a genome of a cell of the population. In some embodiments, the infection is at a sufficiently low MOI such that one virus particle / virion infects one cell. In some embodiments, the infection is at a sufficiently low MOI such that on average one virus particle / virion infects one cell. In some embodiments, the infection is at a sufficiently low MOI such that the majority of cells receive only one virus particle / virion.

[0144] In some embodiments, the third barcode of the first library is different than the third barcode of the second library. In some embodiments, the third barcodes distinguish between cells of the first population and cells of the second population. In some embodiments, the third barcodes distinguish between cells of each population. In some embodiments, cells with the same second barcode and the same first barcode are clonal cells. In some embodiments, clonal cells are all descendant from the same cell.

[0145] In some embodiments, the method comprises mixing the first barcoded population and the second barcoded population prior to the administering. In some embodiments, the method comprises mixing a plurality of barcoded populations. In some embodiments, the first and second barcoded populations are administered separately.

[0146] As used herein, the terms “administering,” “administration,” and like terms refer to any method which delivers a composition containing an active agent (i.e., the barcoded cells) to a subject. One aspect of the present subject matter provides for intravenous administration of a therapeutically effective amount of a composition of the present subject matter. Other suitable routes of administration can include parenteral, subcutaneous, oral, intramuscular, or intraperitoneal. Indeed, a xenograft can be implanted into any specific organ or location in a body.

[0147] In some embodiments, the method further comprises extracting a sample from the subject. In some embodiments, the tracking further comprises extracting from the subject a sample. In some embodiments, the sample comprises cells. In some embodiments, the sample is a tissue sample. In some embodiments, the sample is a sample from the site of administration. In some embodiments, the sample is a sample from a site other than the site of administration. In some embodiments, the site is from a site distal to the site of administration. In some embodiments, the sample is a tumor sample. In some embodiments, the sample is an organ. In some embodiments, the organ is lungs. In some embodiments, the organ is liver. In some embodiments, the organ is an organ that has a metastasis. In some embodiments, the organ is an organ that may have a metastasis. In some embodiments, the organ is an organ suspected of having a metastasis. In some embodiments, the sample is from a site of metastasis. In some embodiments, the sample is from a site suspected to have a metastasis.

[0148] In some embodiments, the tracking comprises identifying a nucleic acid molecule comprising the first barcode. In some embodiments, the tracking comprises identifying all nucleic acid molecules comprising a first barcode of the same DNA-binding protein binding site. In some embodiments, the tracking comprises identifying a nucleic acid molecule comprising the second barcode and the first barcode. In some embodiments, identifying is identifying the sequence of the first and the second barcode. In some embodiment, the identifying is in the sample. In some embodiment, the identifying is in barcoded population. In some embodiment, the identifying is in selected cells. In some embodiments, the identifying is in cells of the sample. In some embodiments, the identifying comprises extracting nucleic acid molecules from the sample. In some embodiments, the extracting is extracting genomic DNA. In some embodiments, the identifying comprises detecting the presence of a molecule comprising the second barcode and the first barcode in the extracted nucleic acid molecules. In some embodiments, the first and second barcode are identified in the same nucleic acid molecule. It will be understood by a skilled artisan that reads of only the first or only the second barcode can be discarded as they do not provide unique clonal information.

[0149] In some embodiments, identification of a molecule with a second barcode from the first library indicates the presence of a cell and / or its descendant from the first population. In some embodiments, identification of a molecule with a first barcode from the first library indicates the presence of a specific cell and / or its descendant from the first population. In some embodiments, identification of a molecule with a second barcode from the second library indicates the presence of a cell and / or its descendant from the second population. In some embodiments, identification of a molecule with a first barcode from the second library indicates the presence of a specific cell and / or its descendant from the second population. Thus, a particular cell and its descendants can be tracked by a combination of the two barcodes that define that cell.

[0150] In some embodiments, the identifying comprises identifying the sequence of the barcode. In some embodiments, the identifying comprises sequencing. In some embodiments, the sequencing is next-generation sequencing. In some embodiments, the sequencing comprises deep-sequencing. In some embodiments, the method comprises generating a sequencing library from the extracting nucleic acids. In some embodiments, the method comprises generating a sequencing library from nucleic acid molecules comprising barcodes. Methods of library generation are well known in the art, as are kits for the preparation of such libraries. Any library preparation method and any known sequencing method / apparatus may be used.

[0151] The sequences flanking the barcodes can be used to specifically capture or amplify the barcodes such that sequencing is largely limited to barcode molecules. In some embodiments, the method comprises amplification of the extracted molecules comprising a first and second barcode. In some embodiments, the method comprises isolating extracted molecules comprising a first and second barcode. In some embodiments, a first PCR is performed to amplify sequences comprising a first and second barcode. In some embodiments, the first PCR is performed with primers to regions flanking the first and second PCR. In some embodiments, the first PCR is a first PCR of a nested PCR. Examples of primers for a first PCR can be found hereinbelow.

[0152] In some embodiments, a second PCR is performed to amplify specifically molecules from one library. As such, a primer used for the second PCR may be specific to the second barcode. In some embodiments, the second PCR is a second PCR of a nested PCR. Examples of primers for the second PCR are provided hereinbelow. In some embodiments, the amplification product from the first PCR is used for generating a sequencing library. In some embodiments, the amplification product from the second PCR is used for generating asequencing library. In some embodiments, the method further comprises sequencing the sequencing library. In some embodiments, the identifying comprises barcode- specific PCR. In some embodiments, the PCR is second barcode specific. In some embodiments, the PCR is first barcode specific.

[0153] In some embodiments, the first population and the second population are a test population and a control population. In some embodiments, at least one test population is used in a method of the invention. In some embodiments, at least one test population is used in a method of the invention. In some embodiments, the method further comprises infecting with another library another population. It will be understood by a skilled artisan that the method can include, for example, a third population infected with a third library, a fourth population infected with a fourth library, a fifth population infected with a fifth library, etc.

[0154] In some embodiments, the first population is exposed to a therapeutic agent before the administering. In some embodiments, the second population is exposed to a therapeutic agent before the administering. In some embodiments, both the first and second populations are exposed to a therapeutic agent before the administering. In some embodiments, a therapeutic agent is a therapeutic treatment. In some embodiments, the control population is known to be resistant to the therapeutic agent. In some embodiments, the control population is not exposed to the therapeutic agent. In some embodiments, the control population is known to be refractory to the therapeutic agent. In some embodiments, the response of the test population to the therapeutic agent is unknown.

[0155] In some embodiments, the method comprises quantifying the number of nucleic acid molecule comprising a given first and second barcode, thereby quantifying the number of cells of a specific clone. In some embodiments, the method comprises quantifying the number of nucleic acid molecule comprising a given first and second nucleic acid barcode, thereby quantifying the number of cells of a specific lineage. In some embodiments, a given first and second nucleic acid barcode is a specific first and second barcode. In some embodiments, the number of first barcodes is quantified. In some embodiments, quantifying is quantifying the number of nucleic acid molecules comprises each second barcode and each distinct first barcode. In some embodiments, the quantifying quantifies the number of specific clones. In some embodiments, the quantifying quantifies the number of cells in each clone. In some embodiments, a clone is a clone of cells with the second barcode. In some embodiments, the clones provide the heterogeneity of a population comprising a specific second barcode.

[0156] In some embodiments, the method further comprises normalizing the number of barcodes. In some embodiments, the method further comprises normalizing the number of barcodes from the first population by the number of barcodes from the second population. In some embodiments, the normalizing is normalizing of the number of molecules with a barcode form the first population. In some embodiments, the normalizing is normalizing of the number of molecules with a specific or given first and second barcode. In some embodiments, the number of molecules from a specific clone / lineage are normalized. In some embodiments, the normalizing is to another clone / lineage of the same population. In some embodiments, the normalizing is to a different population. In some embodiments, the number of barcodes from a given / specific cell of the first population is normalized to the number of barcodes from a given / specific cell of the second population. In some embodiments, barcodes from a test population are normalized by barcodes from a control population.

[0157] In some embodiments, the method is a method of measuring metastasis. In some embodiments, measuring is quantifying. In some embodiments, measuring is tracking. In some embodiments, the first population is a cancer population. In some embodiments, the second population is a cancer population. In some embodiments, the population is a cell line. In some embodiments, the cell line is a cancer cell line. In some embodiments, the population is primary cancer cells. In some embodiments, the primary cancer cells are primary tumor cells. In some embodiments, the population is a patient-derived population. In some embodiments, a patient derived population is primary cells from a patient that have been cultured. In some embodiments, the population is from the same type of cancer as a patient. In some embodiments, the population comprises the same mutation as is found in a cancer of a patient. In some embodiments, the method is for measuring metastasis for a cancer of patient. In some embodiments, the method is a patient- specific diagnostic method. In some embodiments, the method is a diagnostic method.

[0158] In some embodiments, the method is a method of quantifying metastasis in the sample. In some embodiments, the quantify of a second barcode is proportional to the metastasis in the sample. In some embodiments, the quantify of a first barcode is proportional to the metastasis in the sample. In some embodiments, the quantify of molecules comprising a first and second barcode is proportional to the metastasis in the sample. In some embodiments, metastasis from each population is quantified by the presence of second barcodes from each population. In some embodiments, clonality of metastasis is quantified by presence of first barcodes. It will be understood that the amount of first barcode is indicative of the size / number of cells in a particular metastasis. Thus, if a single cell caused the metastasis all the first barcodes will bethe same. Whereas, if several cells metastasized to the same location there will be a mix of first barcodes.

[0159] In some embodiments, a control population is an untreated population. In some embodiments, a control population is a population with a known level of metastasis. In some embodiments, a control population is a population that does not metastasize. In some embodiments, a control population is a population with high metastasis.

[0160] In some embodiments, the method is a method of testing the effect of a therapeutic agent on metastasis. In some embodiments, the method comprises contacting the first cancer population with the therapeutic agent prior to the administering. In some embodiments, the method comprises contacting the second cancer population with the therapeutic agent prior to the administering. In some embodiments, the method comprises contacting both the first and second cancer populations with the therapeutic agent prior to the administering. In some embodiments, the control population is not contacted with the therapeutic agent. In some embodiments, the control population is mock contacted or contacted with a control agent. In some embodiments, the control population is known to be nonresponsive to the agent. In some embodiments, the control population is known to be refractory to the agent. In some embodiments, the number of barcodes from the test population is normalized to the number of barcodes from the control population. In some embodiments, the first population and the second populations comprise the same cells. In some embodiments, the first population and the second population comprise different cells.

[0161] In some embodiments, the method comprises identifying metastases arising from an individual cell. In some embodiments, the method comprises identifying clonal metastases. In some embodiments, the identifying is by quantifying molecules in the sample with the same first barcode. In some embodiments, the identifying is by quantifying molecules in the sample with the same first and second barcodes. In some embodiments, the identifying is identifying a change in metastases with treatment by the therapeutic agent. In some embodiments, a change is a change in clonality. In some embodiments, the change is a change in the number of cells in a metastasis. In some embodiments, the change is a change is the number of different cells that caused the metastasis. In some embodiments, the number of cells in a metastasis is proportional to the size of the metastasis.

[0162] As used herein, the term "about" when combined with a value refers to plus and minus 10% of the reference value. For example, a length of about 1000 nanometers (nm) refers to a length of 1000 nm+- 100 nm.

[0163] It is noted that as used herein and in the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a polynucleotide" includes a plurality of such polynucleotides and reference to "the polypeptide" includes reference to one or more polypeptides and equivalents thereof known to those skilled in the art, and so forth. It is further noted that the claims may be drafted to exclude any optional element. As such, this statement is intended to serve as antecedent basis for use of such exclusive terminology as "solely," "only" and the like in connection with the recitation of claim elements, or use of a "negative" limitation.

[0164] In those instances where a convention analogous to "at least one of A, B, and C, etc." is used, in general such a construction is intended in the sense one having skill in the art would understand the convention (e.g., "a system having at least one of A, B, and C" would include but not be limited to systems that have A alone, B alone, C alone, A and B together, A and C together, B and C together, and / or A, B, and C together, etc.). It will be further understood by those within the art that virtually any disjunctive word and / or phrase presenting two or more alternative terms, whether in the description, claims, or drawings, should be understood to contemplate the possibilities of including one of the terms, either of the terms, or both terms. For example, the phrase "A or B" will be understood to include the possibilities of "A" or "B" or "A and B."

[0165] It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination. All combinations of the embodiments pertaining to the invention are specifically embraced by the present invention and are disclosed herein just as if each and every combination was individually and explicitly disclosed. In addition, all sub-combinations of the various embodiments and elements thereof are also specifically embraced by the present invention and are disclosed herein just as if each and every such sub-combination was individually and explicitly disclosed herein.

[0166] Additional objects, advantages, and novel features of the present invention will become apparent to one ordinarily skilled in the art upon examination of the following examples, which are not intended to be limiting. Additionally, each of the various embodiments and aspects of the present invention as delineated hereinabove and as claimed in the claims section below finds experimental support in the following examples.

[0167] Various embodiments and aspects of the present invention as delineated hereinabove and as claimed in the claims section below find experimental support in the following examples.EXAMPLES

[0168] Generally, the nomenclature used herein and the laboratory procedures utilized in the present invention include molecular, biochemical, microbiological and recombinant DNA techniques. Such techniques are thoroughly explained in the literature. See, for example, "Molecular Cloning: A laboratory Manual" Sambrook et al., (1989); "Current Protocols in Molecular Biology" Volumes I-III Ausubel, R. M., ed. (1994); Ausubel et al., "Current Protocols in Molecular Biology", John Wiley and Sons, Baltimore, Maryland (1989); Perbal, "A Practical Guide to Molecular Cloning", John Wiley & Sons, New York (1988); Watson et al., "Recombinant DNA", Scientific American Books, New York; Birren et al. (eds) "Genome Analysis: A Laboratory Manual Series", Vols. 1-4, Cold Spring Harbor Laboratory Press, New York (1998); methodologies as set forth in U.S. Pat. Nos. 4,666,828; 4,683,202; 4,801,531; 5,192,659 and 5,272,057; "Cell Biology: A Laboratory Handbook", Volumes I-III Cellis, J. E., ed. (1994); "Culture of Animal Cells - A Manual of Basic Technique" by Freshney, Wiley- Liss, N. Y. (1994), Third Edition; "Current Protocols in Immunology" Volumes I-III Coligan J. E., ed. (1994); Stites et al. (eds), "Basic and Clinical Immunology" (8th Edition), Appleton & Lange, Norwalk, CT (1994); Mishell and Shiigi (eds), "Strategies for Protein Purification and Characterization - A Laboratory Course Manual" CSHL Press (1996); all of which are incorporated by reference. Other general references are provided throughout this document.Materials and Methods

[0169] Cell culture and reagents. All cell lines were obtained from the ATCC. 4T1 and H1975 cells were cultured in RPMI-1640 medium supplemented with 2mM L-Glutamine, 1 % penicillin / streptomycin (pen / strep) and 10% v / v Foetal Bovine Serum (FBS); A549 cells were cultured in Ham’s F12 Nutrient Medium supplemented with 2mM L-Glutamine, 1% pen / strep and 10% FBS; MDA-MB-231 and 293LTX cells were cultured in DMEM, High Glucose ( 4500 mg\L D-glucose) supplemented with 2mM L-Glutamine, 1% pen / strep and 10% FBS and HCT 116 cells were cultured in McCoy's 5 A Medium supplemented with 2mM L- Glutamine, 1% pen / strep and 10% FBS. All the cell culture media and supplements including FBS were purchased from Biological Industries (Israel).

[0170] Cells were routinely cultured in 75 cm2 tissue culture flask and kept in a humidified atmosphere with 5% CO2 at 37°C. The cell lines were validated by STR profiling and are tested for mycoplasma every 4 months.

[0171] FX 9847 was provided by Felicitex Therapeutics, Inc (MA, USA); Osimertinib was purchased from LC Laboratories (MA, USA); Doxorubicin hydrochloride, Irinotecan, 5- Azacytidine were purchased from Sigma- Aldrich (MO, USA).

[0172] Single cell cloning. Colorectal cancer cell line HCT116 was used as a model system; single cell cloning was performed by using limiting serial dilution and cloning disks (Merck, Ca#Z374431).

[0173] Colony formation assay. H1975 and A549 cells were plated in 6-well plates at confluency of 50% and a day later treated with elevated concentrations of osimertinib or with vehicle control. The treatments were 2.5, 5, 7.5, 10, 12.5, 15, 20 pM osimertinib for 7 days then medium was removed and cells were rinsed with PBS. Fixation and staining of clones were done with a mixture of 0.5% crystal violet in 50 / 50 methanol / water for 30 min. Dishes were rinsed with water and left for drying at room temperature. Afterwards, the stain was solubilized in 0.2% Triton X-100 and the O.D.at 590 nm was determined.

[0174] Virus Preparation for Barcode library & shRNA screens. Lentivirus shRNA library was prepared using the corresponding plasmids of screens along with virus coat packaging plasmids using Lipofectamine3000 infection reagent in 293LTX cells. Briefly, cells were passaged and grown at 80-90% confluency in DMEM high glucose media supplemented with 4mM glutamine, ImM sodium pyruvate and 5% heat inactivated FBS. As per transfection protocol reagents were mixed in opti-MEM (Cat# 31985070, Thermo) supplemented with 4mM glutamine and co-incubated for overnight. Next day media was changed with OptiMEM supplemented with 5% FBS, 4mM glutamine and kept further for 24 hours. Virus were harvested using 0.45 pm filter and kept in -80C for further use.

[0175] Library for Barcoding cells + My Barcode library. In the initial phase the cells were barcoded with 50M library as per manufacturer protocols, a methodology by which the cells can be barcoded with 18 nucleotide unique barcodes developed by Cellecta Inc (Cat#BC13X13-P) which enables one to tag individual cells with unique barcode that later can be tracked at single cell level to its progeny as the barcodes integrates into genomic DNA and passed to further progeny.

[0176] Infection of the cell line with 50M Lentiviral Library. First, cells were infected with above 50M library in a lentiviral vector. The MOI is sufficiently low such that on average eachcell receives only one viral particle. After infection of cells, it is selected by puromycin and further divided into groups for drug treatment in presence or absence of 5 -azacytidine. Cells are then allowed to recover back following which is harvested and genomic DNA isolation was done, prepared for NGS pipeline and data analysis was performed. Doing so followed by chosen treatment with drug would kill the sensitive cells carrying the barcodes and only resistant cells will recover back. Comparing above treatments with control having no treatment gives information about the clones that survived in major treatment options, unveiling effects due to the drug.

[0177] Xenografts. All animals were housed under pathogen-free conditions and the experiments were conducted in compliance with NIH / USDA guidelines, under the approval of the Ariel University Institutional Animal Care and Use Committee. Cell line suspensions were prepared in 1:1 matrigel (ECM Gel #E1270, Sigma- Aldrich, MO, USA) and approximately 1.5 x 106cells were subcutaneously injected into the flanks of 9-week-old female nude (Nu / Nu) mice (Envigo, Israel). Tumors were measured with calipers and the tumor volume was calculated according to the formula Vol = 0.52 x L x W2. When tumors reached the volume of approximately 200-300 mm3, mice were randomly assigned into either treatment group or control group. Doxorubicin hydrochloride (5 mg / kg) was administered intraperitoneally trice weekly, FX 9847 (40 mg / kg, 0,05% DMSO final cone.) was administered intraperitoneally once daily and osimertinib (2.5 mg / kg) was administered by oral gavage once daily.

[0178] Tumor volumes were measured, and body weights were monitored twice weekly for the entire span of the experiment.

[0179] Genomic DNA extraction and amplification of barcodes. DNA from primary tumor was extracted with standard proteinase K digestion (Proteinase K, # EO0491, Thermo Scientific, MA, USA) and phenol / chloroform extraction followed by ethanol precipitation repeated twice while DNA from liver and lung was isolated with an DNeasy Blood & Tissue Kit (Qiagen, Germany) followed by additional clean up using DNeasy PowerClean Pro Cleanup Kit (Qiagen, Germany) according to the manufacturer’s protocols. Isolation of genomic DNA from recovered cells was performed by Wizard genomic DNA isolation kit (Promega, WI, USA).

[0180] Amplification of the barcodes was carried out by nested PCR.

[0181] Briefly, 1-st PCR (PCR 1) was performed using Titanium Taq DNA Polymerase (# 639209, Takara Bio, CA, USA) for all above experiments. Separation of the PCR productsfrom primers and gel purification was done by QIAquick PCR & Gel Cleanup Kit (Qiagen, Germany) in order to remove the primers and any non-specific genomic DNA amplifications. Afterwards, 2-nd PCR (PCR 2) was carried out using nested primers having unique sample barcodes as two rounds of nested PCR are necessary to increase the specificity of polymerization. PCR 2 was performed using Phusion High-Fidelity PCR Master Mix (Thermo Scientific, MA, USA), Therefore, we first PCR using a wider separated primer to a region that covers the barcode, and then perform a second PCR reaction with primers that are closer to each other but still cover the barcode. Afterwards, all the samples were multiplexed and normalized individually before pooling and therefore purification of the PCR products was completed using AmpureXP magnetic beads (Beckman Coulter, CA, USA) following manufacturer protocols. Next step was performed by sequencing of the barcodes using Ion Torrent sequencing, done as a service by a commercial provider.

[0182] Analysis of genetic screen data. A custom-tailored software was used to analyze sequencing results along with R packages. Second barcodes were demultiplexed and separate FASTAQ files were obtained, further this file was used to count the unique barcodes using grep function of Linux based command line. Next, the correspondence between the sequenced barcodes in the first experiment of barcode libraries and the treated one was found, which enables finding out the unique barcodes that are abundant after treatment. In parallel, unique clonal line quantification in the population was performed. For data cleaning R-Package was used.

[0183] Quantitative PCR. qPCR was performed using PerfeCTa SYBR Green FastMix (Quantabio, MA, USA) according to the manufacturer's protocol with a StepOnePlus™ machine (Applied Biosystems, CA, USA) (30 sec at 95C, followed by 40 cycles of 95C for 3 sec; 65C for 15 sec; 70C for 40 sec). Finally, a melting curve was recorded for 15 sec. at 95°C, 1 min at 60°C and 15 sec at 95°C. Data were analyzed using StepOne™ v2.3 Software.

[0184] Statistical analysis. Statistical analysis was performed on Graphpad Prism and R programming language. Data are expressed as mean +SD. Student's T test and one-way analysis of variance (ANOVA) were used to evaluate the statistical significance of difference in two and more groups, respectively. Benjamini-Hochberg correction method (FDR) was used to correct for multiple comparisons. P-value less than 0.05 was considered as significant.

[0185] Detailed procedure of PCR and primers

[0187] Forward-5 ’-ion-torrent adaptor {Sample_barcode (6nt)-GAT] -Aligned sequence- 3 ’Reverse-5 ’-Adaptor Pl -Aligned sequence-3’.

[0188] PrimersBare 22_fw AGAAGATTCTAGACTTGTCAC (SEQ ID NO: 37)

[0189] PCR reaction conditions

[0190] PCR reaction conditions for Tumor samples1in the doxorubicin treatment experiment.2in the osimertinib / FX9847 treatment experiment.

[0191] PCR reaction conditions for Lung and Liver samples

[0192] 50M library amplification

[0193] Infection of the cell line with 50M Lentiviral Library. First, cells were infected with above 50M library in a lentiviral vector. The MOI is sufficiently low such that on average each cell receives only one viral particle.Example 1: Double barcoding system.

[0194] Previously, monitoring cancer development with cell barcoding was done using either one barcode or a barcoding library with random barcodes that allowed individual labeling of clones within the cancer cell population. To achieve quantitative evaluation of cancer parameters, the necessity of internal controls for normalization became apparent. In other words, if for example, one sought to test effects of a drug on a cancer cell population, one needed to simultaneously inject in mice both drug-sensitive and drug-resistant cells, and a change in their ratio following the treatment would quantitatively reflect the effect of the drug. Indeed, in the section below about drug effects, it is demonstrated that such internal normalization strongly reduces deviations between different animals. Simultaneous injection of different cell populations, e.g., different cells lines or different mutants within one cell line, also allows quantitative comparison of their ability to form tumors and metastasis. To be able to simultaneously monitor different cell populations and their clonal structure, a series of barcoding libraries with two barcodes was constructed (see Materials and Methods). The 8- nucleotide second barcode was unique for each library, and the 12-nucleotide first barcode that follows the second barcode contained random sequences for labeling individual cells (Fig. 1A). While the second barcode labels a cell variant / line, the first barcode labels individual cells within this line, and thus allows quantification of their progeny, e.g., whether a cell could form a metastasis and how big this metastasis is. The size of each library varied between 40,000 and 200,000 first barcodes. After barcoding, cells could be treated in vitro or injected into animals. To study primary tumors, the tumors were isolated from the sacrificed animals and the barcodes were isolated by nested PCR (see Materials and Methods). To study metastasis, lysates were prepared from the entire harvested organ (liver and both lungs). Samples of the lysates containing 10 mg of protein were taken for DNA isolation. DNA purification is an important step since impurities can significantly affect further PCR steps for the barcode amplification (see Materials and Methods). 5 micrograms of DNA were used for the nested PCR to amplify barcodes, which were then sequenced by either lonTorrent or Illumina NGS.Example 2: Monitoring tumor formation and metastasis by human and mouse cancer cells.

[0195] Four cancer lines were barcoded by four different libraries, including human lung cancer A549, breast cancer MDA-MB231 , ovarian cancer HeLa, and mouse breast cancer 4T 1. Equal numbers of barcoded cells (500,000 each) from each cell line were mixed together and injected into flanks of nude mice to establish xenografts (three mice per group). After the tumors reached about 1 cmA3, animals were sacrificed, and tumors were collected along with lungs and livers. Following DNA isolation and sequencing, barcodes were analyzed. When calculating the ratios of representation of 4T1 and A549 cells in tumors and metastasis, it was found that standard deviations of these ratios in primary tumors were around 20%, which is significantly lower than deviations usually obtained by conventional methods of tumor measurements. In metastasis, the standard deviations of these ratios were 30-40%, which is also lower than usually obtained by either imaging or direct counting of metastasis. Lower deviations in cancer cell representation obtained by cell barcoding over the standard methods is understandable since there are significant variabilities upon injection of cells and establishing primary tumors. These variabilities are reduced upon normalization of samples by internal controls, i.e., comparison of representation in primary tumors of different cell lines injected simultaneously and forming tumors in the same animals. With this level of precision, three to four animals per group is sufficient for almost any study of drug effects on tumor parameters (see below).

[0196] These experiments, with injection of several lines simultaneously, allowed comparative analysis of the ability of cells to establish primary tumors and their metastatic capacities. Unlike conventional methods, which do not allow detecting very small metastasis of human cancers that spread from primary tumors in nude mice, measuring barcodes provides sufficient sensitivity to detect such metastasis and evaluate them quantitatively (see below). This advantage opens a possibility to reproduce all stages of the metastatic process in nude mice, and to test effects of drugs on these stages.

[0197] An important concern was whether cells in mixture affect each other’s growth in tumor and affect metastasis. To address this question, a similar experiment was performed, but instead of injecting four lines, a mixture of only two of them 4T1 and A549 was injected. Accordingly, this mixture lacked MDA-MB231 and HeLa cells. Removal of these cell lines from the injection mixture did not significantly affect either tumor sizes measured by caliper, representation of A549 and 4T1 cells in primary tumors and metastasis, or response to doxorubicin (see below). Therefore, the effects of MDA-MB231 and HeLa cells on tumor formation and metastasis of two other cell lines were insignificant, suggesting that cells in the injection mixture do not considerably affect each other.

[0198] Interestingly, the ability of cells to establish primary tumors and their metastatic capacities did not correlate with each other. For example, there was very low representation of MDA-MB231 cells in the primary tumor, and much higher representation in both liver and lung metastasis, compared to A549 cells (Fig. IB). Of note, HeLa cells appeared to lead to slow cancer development, since following animal sacrifice a week after tumor cell injection, only a very small population of these cells in either primary tumor or metastasis was detected as compared to A549 cells (not shown).

[0199] Next, second clonal barcodes in metastasis formed in lungs and liver were compared. There was a very significant overlap in these two fractions (20%), indicating that if a cell can form metastasis in lungs, it has a high chance forming metastasis in liver (Fig. 1C). Furthermore, faster growing metastasis were able to better populate both lungs and livers (Fig. ID). In contrast, there was no correlation between the ability of cells to propagate in primary tumors and the size of metastasis that they produce (Fig. ID). Accordingly, evolution of metastatic properties provides advantages for metastasis in both organs.Example 3: Using barcoding to quantify drug effects.

[0200] Further, the ability of the barcoding technology to detect effects of doxorubicin treatment on metastasis was tested. Mice with tumors established from a mixture of 4T1, A549 and MDA-MB231 cells were administered doxorubicin, as described hereinabove. Harvested tumors, lungs and livers were used to isolate barcodes, as described above. Significant differences in representation of the cell lines in primary tumors from control and doxorubicin- treated animals were not observed. However, there was a strong change in ratios of metastasis formed by A549 cells compared to other lines. Indeed, a dramatic reduction in representation of A459 in both lungs and livers was detected (Fig. 2A).

[0201] To understand whether different cell lines mixed upon injection into animals affect each other’s drug responses, responses to doxorubicin in animals injected with A549 and 4T1 cells, or the same cells plus MD-MB231 and HeLa were compared. In animal with two cells lines, in primary tumors minimal change in average ratio of A549 to 4T1 was observed following doxorubicin treatment, and comparable change was seen in animals injected with four cell lines (0.61 and 0.73, respectively). In liver metastasis, however, A549 / 4T1 average ratio change was 0.17 in animals with two cell lines and 0.12 with four cell lines. These data indicate that (a) doxorubicin causes a significant reduction in representation of A549 compared to 4T1 cells, and (b) such a change in representation (i.e., drug response) is independent of the presence of two additional cancer cell lines, one of which metastasizes very actively (seebelow). Therefore, there seem to be no significant influence of various cancer cell lines on the primary tumors and metastatic behavior of each other.

[0202] Quantifications of the number of first barcodes present in these organs allowed for independently evaluating how many metastases were established there. Figures 2A and 2B show that doxorubicin both reduced the number of A459 metastasis that spread to lungs and liver and reduced their size. Plotting a distribution of barcodes in control and doxorubicin- treated metastasis according to their representation in lungs and livers (according to number of reads representing each barcode) was very informative. Indeed, the shape of the distribution curve seen in untreated animals significantly changed following doxorubicin treatment (Fig. 2C-2D). These graphs clearly show that doxorubicin both eliminates cell clones (those at the right of the graph) that can populate these organs, and reduces the size of the metastatic clones (those to the left of the graph), i.e., suppresses propagation of cells that were able to spread there. In this experiment there was not a negative control or a spike DNA control in order to quantitatively evaluate effects of the drug. Only relative effects of the drug on different cells lines were evaluated. Therefore, it can only be said that A549 metastasis are about 10-time more sensitive to doxorubicin than 4T1 metastasis.

[0203] Next, the advantages of barcoding in quantifying drug effects on primary tumors and metastasis we investigated when a negative control was introduced. For example, an inhibitor of mutant EGFR, Osimertinib, and an inhibitor of Dyrklb kinase, FX9847, were chosen. They are currently at the preclinical stage of development. The later inhibitor, as do other inhibitors of Dyrklb, returns quiescent cancer cells that are normally drug resistant to the cell cycle, which makes them drug sensitive. Conventional monitoring of the effects of these inhibitors and their combination on tumor growth by lung cancer H1975 cells is shown in Figure 3A. Clearly, FX9847 alone demonstrates minimal suppression of the tumor growth. On the other hand, Osimertinib has a strong tumor-suppressing effect, and combination with FX9847 significantly enhances its anticancer effect. To evaluate this new approach, Hl 975 lung cancer Osimertinib-sensitive cells and A549 lung cancer cells that are more Osimertinib-resistant were barcoded with two different two-barcode libraries, as in the previous experiment. It was confirmed that Hl 975 is more sensitive to Osimertinib than A549 cells in cell culture (Fig. 3B). Equal numbers of cell of these two cell lines were injected into nude mice and the mice were administered either Osimertinib, FX9847, a combination of the two or sham. Following treatments, animals were sacrificed, and tumors, lungs and livers collected. DNA was isolated, and barcodes amplified and sequenced, as in the previous experiments.

[0204] Overall barcode representation indicated that in untreated animals Hl 975 cells have significantly higher ability to form tumors than A549 (Fig. 3C). On the other hand, treatment with Osimertinib strongly changed the ratio between these two cell types in the primary tumors. Though FX9847 alone only slightly changed the ratio between these cells, it enhanced the effect of Osimertinib 2-fold (Fig. 3C). These data were in line with the data obtained by the conventional measurements of tumor sizes (Fig. 3A). Though only three mice per group were used, the statistical significance of these effects was sufficient, since the data was normalized by the internal negative control (i.e., resistant cell line).

[0205] To illuminate the importance of the internal normalization, deviations from the average of the number of reads or the number of barcodes belonging to Hl 975 cells in the primary tumors in three mice were compared to the deviations from the average when these reads and barcodes were normalized by A549 cells in the same mice. Indeed, normalization strongly reduced standard deviations from the average number of reads, and an even stronger effect of normalization was seen with regards to the number of barcodes (Fig. 3D). Therefore, internal normalization using mixtures of cell populations reduces deviations within animal groups, thus allowing the use of smaller number of animals per group.Example 4: Normalization could be achieved even in the absence of data with drugresistant line.

[0206] In the experiment described above, the effect of drugs on the sensitive line was normalize in comparison to the resistant line. There are two sources of variability in measuring barcodes, including (1) variability in the ability of different animals to form primary tumors and metastasis and to respond to drugs, and (2) technical variability related to differences in tissue disruption, isolation of DNA and performing PCR. Comparison of sensitive and resistant lines in one tumor normalizes both of these factors. However, with many drugs, resistant lines are not available or are difficult to select, and therefore normalization to reduce only the technical variability would be sufficient to obtain significant drug effects. Another important question addressed here was whether barcode quantification could be done via quantitative real-time PCR (qPCR) rather than NGS to reduce the cost of the work and make the technology more available for general lab use.

[0207] In principle, it may be possible to normalize metastasis by the total DNA in the tissue sample, while primary tumors could be normalized by the total tumor mass. These approaches, however, are problematic because different DNA preparation have slightly differentcontamination levels, which dramatically affects the first round of the nested PCR, making such normalization practically impossible.

[0208] To address this problem, a different approach was used by spiking standard DNA with similar barcodes and normalizing by it. The idea was that if a tumor DNA sample, after isolation, carries a contamination that affects nested PCR, it would equally suppress PCR of barcodes from tumor and control DNAs. Accordingly, the ratio between PCR products from tumor and control DNA will not be dependent on the presence of contaminations. To obtain control DNA, MDA-MB231 cells were barcoded in cell culture using a library from the two- barcode series with a distinct barcode 1 that was not previously used in the experiment. Total DNA was isolated from these cells and kept as a control. It was important to use the same type of library, since the first round of nested PCR involves the same primers for all DNA types. Distinguishing between different DNA types takes place only at the second PCR, where one of the PCR primers was specific for each barcode 1 in either tumor or control DNA samples. DNA with barcodes isolated from tumor or organs was mixed with the control DNA 4:1, and the first round of the barcode isolating nested PCR was done. The fragment having the mixture of control and tumor barcode types was gel-purified, and in the second round of nested PCR, qPCR with primers that amplify either tumor or tissue barcodes or control barcodes were used.

[0209] Normalization by the spike control DNA showed that significant effects of Osimertinib and FX9847 on Hl 975 cells can be detected by qPCR even without normalization by the resistant cell line (Fig. 4A). In these samples, there was no reduction in representation of A549 cells, but rather even an increase in their representation because of normalization. Therefore, this approach controls for contaminations and PCR conditions, and allows normalization in the absence of negative control cell line. However, as expected, when an additional normalization step was done by getting a ratio of H1975 / A549 barcode representation, more significant effects of drugs were obtained, so that even effects of FX9847 became significant (Fig. 4B).Example 5: Clonal responses to drugs.

[0210] Cell barcoding allowed the uncovering of some novel mechanistic features of drug actions. At the next step the distribution of barcodes was plotted by the number of reads, i.e., individual clones within the tumor by their sizes. Figure 5A shows a typical distribution curve in untreated tumors (orange line). Treatment with FX9847 did not change either the shape of the curve or its position (blue line), confirming the minimal effect of FX9847. In contrast, Osimertinib strongly shifted down the entire curve without changing its shape (green line).This finding indicates that Osimertinib equally suppresses growth or kills cells derived from different barcode-labeled clones. In other words, there was little clonal variability in sensitivity to Osimertinib in cells that formed the primary tumor. Combination of Osimertinib and FX9847, while reducing the ratio of representation of H1975 versus A549 only two-fold (Fig. 3C), dramatically changed the shape of the curve (Fig. 5A, red line). This combination produced an almost 5-fold reduction in the number of clones that survived the treatment. These data indicate that addition of FX9847 to Osimertinib did not equally suppress the growth of all barcoded clones, but rather led to elimination of a large number of clones (loss of clones on the right side of the chart) while reducing the growth of some (middle clones shifted lower than the Osimertinib alone line) and completely sparing the others (clones all the way to the left that overlap with the Osimertinib alone line). In other words, there was a strong variability in sensitivity to FX9847 when combined with Osimertinib. Therefore, these experiments uncovered two fundamentally different effects of drugs on cancer cell populations, one type of drug affects cells independently of their clonal properties, while the other type of drugs affects cells depending on their clonal origin.

[0211] Compared to primary tumors, in lung metastasis the effects of Osimertininb either alone or in combination with FX9847 were significantly lower (Fig. 5B-5C), although a similar effect was observed for the combination treatment with some clones completely eliminated and others only modestly effected. These data suggest that some metastases acquired resistance to Osimertinib, which could be abrogated by the addition of FX9847.Example 6: Different drugs show different clonal effects.

[0212] Finding that different drugs have different clonal effects, while others suppress the entire clonal population, could be significant for designing treatment strategies and finding novel drug combinations. In fact, if there is a strong clonal selectivity in response to a certain drug, probably dose escalation of this will does not make much sense, while for drugs that affect the entire population of cancer cells, dose escalation could be beneficial. Notably, these considerations need to be tested since even with the latter mechanism of action, dose escalation may fail due to selection of resistant versions. Accordingly, two more drugs were tested for their effects on clonal populations, including a topoisomerase 1 inhibitor, irinotecan, and an inhibitor of DNA methylation, 5-azacytidine. Since these drugs are used for treatment of colon cancer, in this experiment a colon cancer cell line HCT116 was used. Irinotecan was titrated and an IC50 of 20nM was identified. 5-azacytidine alone did not kill these cells even at high concentrations, but it significantly sensitized cells to irinotecan (not shown). In the initialexperiment, cells were barcoded and exposed in culture to irinotecan. Distribution of barcodes demonstrated that irinotecan both shifts the curve down and changes its shape (Fig. 6A), suggesting that it has both effects on the entire population and some stronger killing effects on a clonal subpopulation. In an attempt to dissociate these effects, the cultured population of HCT116 cells were cloned to obtain genetically identical populations. One of the clones was barcoded and exposed to irinotecan. With cloned cells irinotecan could only shift the barcode distribution curve down without changing its shape (Fig. 6B). Accordingly, with genetically uniform cell population irinotecan suppresses growth or kills cells of the population uniformly. Irinotecan sensitivity was tested of several clones obtained from the original cell line and it was found that they show almost 20-fold variability in IC50 towards irinotecan, ranging from 2 to 40nM. Therefore, original clonal effects of irinotecan were associated with the genetic heterogeneity of the cell line, and these effects were diminished in the genetically uniform population.

[0213] Effects of 5-azacytidine on HCT116 cells were very different. In the heterogeneous population, 5-azacytidine added together with irinotecan, both shifted the size distribution curve and changed its shape even more strongly than irinotecan alone (Fig. 6A). However, when its effects were tested in the genetically homogeneous cloned population of cells, addition of 5-azacytidine together with irinotecan was observed to change the shape of the curve, demonstrating that 5-azacytidine effectively eliminates a subset of clones without touching the rest of the population (Fig. 6B). Therefore, here again, two different types of drugs with different clonal effects were found. Notably, only the barcoding approach allows clear definition of these drug types, which could be important for designing of the treatment strategy.Example 7:

[0214] As it is clear that the double barcoding system allows for the detection and quantitation of clonal heterogeneity in cell populations, it was put to use to improve the accuracy and decrease the false-positive rate during forward genetic screening. High-throughput CRISPR and shRNA based genetic screening is commonly used to determine drug targets, genes relevant to specific disease or drug response. Unfortunately, the greatest drawback of these screens is a high false positive rate. Genes whose knockdown / out appears to produce the target phenotype (e.g., drug resistance) are all too often found to not be true targets upon validation.

[0215] To overcome this problem the double barcoded library is integrated into a CRISPR or shRNA library. In a standard CRISPR / shRNA library, cells are infected with the library andthen exposed to some test condition (e.g., a drug), cells with the target phenotype (e.g., survival) are harvested and the gene which was downregulated / knockout can be identified by the shRNA or gRNA itself or by a barcode which identifies the knocked out / down gene (Fig. 7A). However, this system does not provide any information on the clonality of the cells that survived. It could be that all cells with a particular gene knockdown / out indeed survived, or it could be that in fact most of the cells died, but a specific clone survived due to some other intrinsic resistance present in one particular cell which then propagated (Fig. 7B). This heterogeneity cannot be distinguished using the presently available libraries, and these cases of heterogeneity lead to false hits.

[0216] A double barcoded CRISPR / shRNA library (Fig. 7C) solves this problem. Whereas in the old method sequencing might identify 5 copies of a given barcode corresponding to knockdown of a specific gene, the new method would identify 5 copies based on the second barcode, but then based on the first barcode would know if those copies came from 5 different clones (Fig. 7D, shRNA-2) or if they all came from the same clone (Fig. 7D, shRNA-5). In the example presented in Figure 7D the standard method would identify the targets of shRNA- 2 and shRNA-5 as equally good candidates, whereas use of the double barcoded library would identify the target of shRNA-5 as likely a false positive.Example 8:

[0217] The double barcoding library was also used in the context of transcription reporters (Fig. 8). Individual plasmids containing a transcription factor binding site (also called a transcriptional response element, TRE) upstream of a minimal promoter which is then operatively linked to a fluorescent reporter are used to measure transcription factor (DBP) activity in cells. However, these constructs are limited in that only a single DBP can be monitored at a time. Instead of, or in addition to, the fluorescent reporter, a second barcode can be operatively linked to the DBP promoter. A unique second barcode can be assigned to each DBP being investigated and thus the activity of a large number of DBPs can be examined simultaneously. Further, the first barcode provides cell specific information on the activity of the DBP, once again solving the problem of cellular heterogeneity. Indeed, a third barcode can even be added to label the entire library and thus distinguish it from a second library that was administered to a different cellular population. Sequencing of the produced RNA would serve as the output for monitoring the DBP activity which is far more quantifiable and multiplexable as compared to fluorescent protein production.

[0218] Following standard design of signaling reporters, a lentiviral library that has the design shown on Figure 8 was constructed. It contains: (a) four repeats of a TF-binding sequence (4X-TRE), (b) minimal CMV promotor (minCMV) transcribing a unit of (c) barcode 2 (BC2) specific for each TF, (d) random barcode 1 (BC1) to allow labeling of individual cells within a population, and (e) short BC3 that labels the entire library and thus the entire cell population that carries this library. Two libraries were constructed with different BC3 to label different populations. There are 688 TFs and related DNA-binding proteins in the human genome. 177 of them share binding sequences with at least one other TF and their specificity is defined by neighboring regions. Though this approach cannot consider these regions, single 4X-TREs for such groups of TFs were included. Altogether, the libraries cover 569 4X-TREs (511 for individual TFs and 58 for groups of TFs). Each type of 4X-TRE (BC2) is represented by a diversity of 100-400 plasmids (BC1), and thus allows individual labeling of the corresponding numbers of cells.

[0219] Importantly, because of different rates of proliferation and death, different number of cells will carry each construct. Therefore, to obtain information about TF activities, one needs to normalize the expression of each construct (relative number of reads in mRNA) by the number of cells that carry that construct (number of reads in the whole cell DNA). The latter information can also inform about the ability of cells to proliferate or die (see such an analysis in Hesin et al, “A Cell Double-Barcoding System for Quantitative Evaluation of Primary Tumors and Metastasis in Animals That Uncovers Clonal-Specific Anti-Cancer Drug Effects”, Cancers (Basel). 2022 Mar 8; 14(6), the contents of which are hereby incorporated herein by reference in their entirety).

[0220] Her2-positive BT474 cells were infected with the library, and the barcodes sequenced and analyzed. Figure 9A shows data on the number of reads in RNA and DNA for a single TF across a set of clones, and the result of normalization. Whereas before normalization little information about TF activity can be gleaned, Figure 9B shows the distribution of normalized TF activities across multiple clones (BC1) for two TFs (YAP and Hifl). One can clearly see two different scenarios: (a) Hifl is similarly active in all clones, but (b) there are two subpopulations with very different activities of YAP. This demonstrates the utility of the two- barcode system for measuring transcription factor activity. This benefit is not possible without being able to distinguish individual clones.Example 9:

[0221] The double barcoding library can also used in the context of microRNA (miR) reporters (Fig. 10). Individual plasmids contain a strong, constitutively active promoter (e.g., the CMV promoter) which is operatively linked to a fluorescent reporter (e.g., GFP). A microRNA (miR) binding site is inserted either in the coding region of the reporter or more simply within the 3’ UTR. Additionally, a second barcode can be operatively linked to the promoter. A unique second barcode can be assigned to each miR being investigated and thus the activity of a large number of miRs can be examined simultaneously. Further, the first barcode provides cell specific information on the activity of the miR, once again solving the problem of cellular heterogeneity. Indeed, a third barcode can even be added to label the entire library and thus distinguish it from a second library that was administered to a different cellular population. Detecting the reporter or sequencing of the produced RNA would serve as the output for monitoring the miR’s activity.

[0222] Following standard design of signaling reporters, a lentiviral library that has the design shown on Figure 10 is constructed. It contains: (a) CMV promoter transcribing a unit of (b) a fluorescent reporter protein (e.g., GFP) (c) a miR binding site, (d) barcode 2 (BC2) specific for each miR, (e) random barcode 1 (BC1) to allow labeling of individual cells within a population, and (f) short BC3 that labels the entire library and thus the entire cell population that carries this library. Two libraries are constructed with different BC3 to label different populations. Altogether, the libraries cover 3000 miRs and each type is represented by a diversity of 100-400 plasmids (BC1), and thus allows individual labeling of the corresponding numbers of cells.

[0223] Importantly, because of different rates of proliferation and death, different number of cells will carry each construct. Therefore, to obtain information about TF or miR activities, one needs to normalize the expression of each construct (relative number of reads in mRNA) by the number of cells that carry that construct (number of reads in the whole cell DNA). The latter information can also inform about the ability of cells to proliferate or die (see such an analysis in Hesin et al, “A Cell Double-Barcoding System for Quantitative Evaluation of Primary Tumors and Metastasis in Animals That Uncovers Clonal-Specific Anti-Cancer Drug Effects”, Cancers (Basel). 2022 Mar 8; 14(6), the contents of which are hereby incorporated herein by reference in their entirety).

[0224] Although the invention has been described in conjunction with specific embodiments thereof, it is evident that many alternatives, modifications and variations will be apparent to those skilled in the art. Accordingly, it is intended to embrace all such alternatives, modifications and variations that fall within the spirit and broad scope of the appended claims.

Claims

CLAIMS:

1. A library of nucleic acid molecule vectors, wherein each vector of said library comprises: a. a promoter comprising a sequence of a DNA-binding protein binding site and a sequence of a minimal promoter; and b. a first nucleic acid barcode; wherein said first nucleic acid barcode is unique to each vector of said library; wherein said first nucleic acid barcode is operably linked to said promoter, and said library contains a plurality of vectors with the same sequence of a DNA- binding protein binding site and each vector of said plurality of vectors comprises a unique first barcode.

2. The library of claim 1, wherein each vector of said library further comprises a second nucleic acid barcode unique to said DNA binding protein binding site, and wherein said plurality of vectors with the same sequence of a DNA-binding protein binding site comprise the same second nucleic acid barcode.

3. The library of claim 1 or 2 wherein said library comprises vectors with a DNA-binding protein binding site for at least 2 different DNA-binding proteins, optionally wherein at least 2 is at least 10.

4. The library of claim 3, wherein said library contains a plurality of vectors with the same sequence of a DNA-binding protein binding site for each of said at least 2 different DNA- binding proteins.

5. The library of any one of claims 1 to 4, wherein said DNA-binding protein is a transcription factor.

6. The library of any one of claims 1 to 5, wherein said DNA-binding protein is a component of a histone binding complex.

7. The library of any one of claims 1 to 6, wherein said DNA-binding protein is component of a DNA-modification complex.

8. The library of any one of claims 1 to 7, wherein said promoter comprises a repeat of said sequence of a DNA-binding protein binding site.

9. A library of nucleic acid molecule vectors, wherein each vector of said library comprises a constitutively active promoter operably linked to: a. a transcribable region; b. a microRNA (miR) binding site; and c. a first nucleic acid barcode; wherein said first nucleic acid barcode is unique to each vector of said library; wherein said library contains a plurality of vectors with the same miR binding site and each vector of said plurality of vectors comprises a unique first barcode.

10. The library of claim 9, wherein each vector of said library further comprises a second nucleic acid barcode unique to said miR binding stie, and wherein said plurality of vectors with the same miR binding site comprises the same second nucleic acid barcode.

11. The library of claim 9 or 10, wherein said library comprises vectors with a miR binding site for at least 2 different miRs, optionally wherein at least 2 is at least 10.

12. The library of claim 11, wherein said library contains a plurality of vectors with the same miR binding site for each of said at least 2 different miRs.

13. The library of any one of claims 9 to 12, wherein said transcribable region is an open reading frame encoding a protein.

14. The library of claim 13, wherein said protein is a fluorescent reporter protein.

15. The library of claim 13 or 14, wherein said miR binding site is within a 3’ untranslated region (UTR) of said open reading frame.

16. The library of any one of claims 1 to 15, wherein said nucleic acid molecule vectors are viral DNA or RNA vectors.

17. The library of claim 16, wherein said viral DNA or RNA vectors are capable of integrating said promoter, said second nucleic acid barcode and said first nucleic acid barcode into a genome of a cell infected by a virus comprising said viral vectors.

18. The library of claim 17, wherein said viral vectors are selected from retroviral vectors, lentiviral vectors and adeno-associated viral vectors.

19. The library of any one of claims 1 to 18, wherein said plurality comprises at least 5 vectors wherein each of said at least 5 vectors comprises a different first barcode.

20. The library of any one of claims 1 to 19, wherein said first nucleic acid barcode, said second nucleic acid barcode or both comprises a nucleic acid sequence not found within a genome of a target cell.

21. The library of any one of claims 1 to 20, wherein said first nucleic acid barcodes are predetermined sequences selected such that each vector of said library comprises a first nucleic acid barcode with a unique sequence.

22. The library of any one of claims 1 to 21, wherein said first nucleic acid barcode is a randomly generated sequence.

23. The library of claim 22, wherein said library has been sequenced such that said DNA- binding protein binding site or said miR binding site and said randomly generated sequence of each vector is known.

24. The library of any one of claims 2 to 8 and 10 to 23, further comprising a linker sequence between said first nucleic acid barcode and said second nucleic acid barcode.

25. A kit comprising at least two libraries of vectors of any one of claims 1 to 24, wherein each of said at least two libraries further comprises a third nucleic acid barcode and where a first library comprises a different third nucleic acid barcode from a third nucleic acid barcode of a second library.

26. The kit of claim 25, wherein said first nucleic acid barcodes, said second nucleic acid barcodes or both of said first library are the same as the first nucleic acid barcodes, second nucleic acid barcodes or both of said second library.

27. The kit of claim 25 or 26, further comprising at least one helper plasmid comprising an open reading frame encoding at least one viral gene required for production of infection- competent virus.

28. A viral library wherein each virion of said library comprises a viral vector from a library of any one of claims 1 to 24.

29. A kit comprising at least two viral libraries of claim 28, wherein each of said at least two libraries further comprises within said viral vectors a third nucleic acid barcode and where a first library comprises a different third nucleic acid barcode from a third nucleic acid barcode of a second library.

30. A method of simultaneously measuring activity of at least two transcription factors in a population of cells, the method comprising: a. contacting a population of cells with a library of any one of claims 2 to 8, 16 to 24 and 28 to produce a barcoded population of cells; b. identifying sequences of first and second barcodes on the same nucleic acid molecule within said double-barcoded cells, wherein the amount of a first second barcode is proportional to the activity of a first transcription factor and the amount of a second second barcode is proportional to the activity of a second transcription factor; thereby simultaneously measuring activity of at least two transcription factors.

31. A method of simultaneously measuring activity of at least two transcription factors in a population of cells, the method comprising: a. contacting a population of cells with a library of claim 23 or 28 to produce a barcoded population of cells; b. identifying sequences of first barcodes on nucleic acid molecules within said barcoded cells, wherein the amount of all first barcodes known to be on vectors comprising a first DNA-binding protein binding site is proportional to the activity of a first transcription factor and the amount of all second first barcodes known to be on vectors comprising a second DNA-binding protein binding site is proportional to the activity of a second transcription factor; thereby simultaneously measuring activity of at least two transcription factors.

32. A method of simultaneously measuring activity of at least two miRs in a population of cells, the method comprising: a. contacting a population of cells with a library of any one of claims 10 to 24 and 28 to produce a barcoded population of cells;b. identifying sequences of first and second barcodes on the same nucleic acid molecule within said double-barcoded cells, wherein the amount of a first second barcode is inversely proportional to the activity of a first miR and the amount of a second second barcode is inversely proportional to the activity of a second miR; thereby simultaneously measuring activity of at least two miRs.

33. A method of simultaneously measuring activity of at least two miRs in a population of cells, the method comprising: a. contacting a population of cells with a library of claim 22 or 27 to produce a barcoded population of cells; b. identifying sequences of first barcodes on nucleic acid molecules within said barcoded cells, wherein the amount of all first barcodes known to be on vectors comprising a first miR binding site is inversely proportional to the activity of a first miR and the amount of all second first barcodes known to be on vectors comprising a second miR binding site is inversely proportional to the activity of a second miR; thereby simultaneously measuring activity of at least two miRs.

34. The method of any one of claims 30 to 33, wherein said vectors are viral DNA or RNA vectors and said contacting comprises infecting said population of cells with said library.

35. The method of claim 34, wherein said infecting results in integration of said second nucleic acid barcode and said first nucleic acid barcode into said population of cells.

36. The method of any one of claims 30 to 35, wherein said identifying comprising extracting nucleic acid molecules from said cells and detecting the presence of a nucleic acid molecule comprising said second nucleic acid barcode and said first nucleic acid barcode in said extracted nucleic acid molecules.

37. The method of any one of claims 30 to 36, wherein said identifying comprises next generation sequencing or barcode-specific PCR.

38. The method of any one of claims 30 to 37, further comprising contacting said barcoded population of cells with a test condition prior or contacting said population of cells with a test condition prior to step (a).

39. The method of claim 38, wherein said test condition comprises contacting said doublebarcoded population of cells with a therapeutic agent.

40. The method of claim 39, wherein said therapeutic agent is a toxic agent and said target phenotype is cell survival or growth.

41. The method of any one of claims 30 to 40, comprising within said identified sequences quantifying the number of nucleic acid molecules comprising each second barcode and each distinct first nucleic acid barcode thereby quantifying the number of specific clones and / or the number of cells in each clone of cells with each second barcode.

42. The method of any one of claims 30 to 41, wherein said population of cells are administered to a non-human subject and said method is a method of simultaneously measuring in vivo activity of at least two transcription factors or at least two miRs.

43. The method of claim 42, for quantifying and / or tracking transcription factor activity in a cancer metastasis.

44. The method of claim 42 or 43, wherein said population is selected from a cancer cell line, primary tumor cells and a patient-derived cancer cell population.